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Extracellular vesicles (EVs), including exosomes and microvesicles (MVs), have 
emerged as a major form of intercellular communication, playing important roles in several 
physiological processes and diseases including cancer. EVs generated by cancer cells contain a 
variety of proteins and RNA species that can be transferred between cancer cells, as well as 
between cancer and non-transformed (normal) cells, thereby impacting a number of aspects of 
cancer progression. We show how oncogenic transformation influences the biogenesis and 
function of EVs using a mouse embryonic fibroblast (MEF) cell line that can be induced to 
express an oncogenic form of Dbl (for diffuse B cell lymphoma). MVs isolated from onco-Dbl-
transformed cells contain a unique signaling protein, the ubiquitously expressed non-receptor 
tyrosine kinase, focal adhesion kinase (FAK). The addition of MVs isolated from MEFs 
expressing onco-Dbl to cultures of normal fibroblasts strongly promoted their survival and 
induced their ability to grow under anchorage-independent conditions, outcomes that could be 
reversed by knocking-down FAK and depleting it from the MVs, or by inhibiting its kinase 
activity using a specific inhibitor. I then showed the same to be true for MVs isolated from 
aggressive MDAMB231 breast cancer cells. Together, these findings demonstrate that the 
induction of oncogenic transformation gives rise to MVs, which uniquely contain a signaling 
  
protein kinase that helps propagate the transformed phenotype, and thus may offer a specific 
diagnostic marker of malignant disease. 
Additionally, I have discovered that treating MDAMB231 breast cancer cells with the 
chemotherapy paclitaxel, which functions by stabilizing microtubules, significantly increases the 
amount of survivin in the EVs shed by these cells. I then go on to show that survivin is 
specifically enriched in the class of EVs known as exosomes. Exosomes collected from 
MDAMB-231 cancer cells treated with paclitaxel promoted the growth and survival of recipient 
fibroblasts and other breast cancer cells exposed to serum-starvation and paclitaxel treatment, an 
effect that was lost when survivin was depleted from these exosomes by siRNA. Overall, these 
results highlight how a specific protein is selectively packaged into exosomes, as well as shed 
light on a potential mechanism underlying paclitaxel resistance. 
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CHAPTER 1 
Introduction 
Intercellular communication is critical for the development and functionality of 
multicellular organisms, while deregulation of these events often cause the onset of disease. A 
classical example of intercellular communication involves the secretion of a soluble factor, such 
as a growth factor or cytokine, by one cell into its local environment (1). The soluble factor then 
binds its corresponding receptor expressed in a neighboring cell, leading to the activation of 
signaling pathways that determines whether the target cell grows, differentiates, migrates, or 
even dies (2, 3). In addition to soluble factor-mediated interactions between two cells, there are 
several other forms of intercellular communication, including direct cell-to-cell contact (4).  
The study of intercellular communication has expanded greatly with the discovery that 
membrane enclosed packets of information, collectively referred to as extracellular vesicles 
(EVs), are actively released by cells (5-8). Once thought to be nothing more than cellular debris, 
it is now appreciated that EVs are an evolutionarily conserved mechanism utilized by 
prokaryotes, eukaryotes, and plants for the transmission of signals by cells (8-12). While there is 
increasing evidence suggesting that EVs play important roles in several different biological 
contexts, to date, most of the studies on EVs have been in the field of cancer biology. Indeed, 
EVs have been shown to be potent mediators of tumor growth, metastasis, vascularization, and 
even chemoresistance (13-15).  
EVs are able to carry out a diverse range of biological functions as a result of the unique 
cargo they contain, including microRNA (miRNA), messenger RNA (mRNA), DNA, cytokines, 
receptor and non-receptor tyrosine kinases, cytoskeletal components, and transcription factors 
1
(16-20). Due to the findings that the contents of EVs often reflect their cell of origin, and that 
EVs can be found in the bloodstream, there are also significant implications for the use of EVs as 
diagnostic markers of disease (21, 22).  
Biogenesis of distinct classes of EVs 
EVs have been referred to by a variety of names, including ectosome, exosomes, 
oncosomes, microparticles, microvesicles (MVs), shedding vesicles, or simply small vesicles 
(23-26). This has created a good deal of confusion in the field, especially because there are 
distinct classes of EVs. The EVs generated by viable cells can be broken down into two major 
classes: 1) MVs, or those EVs that are shed from the plasma membrane, and 2) exosomes, or 
those EVs that are formed by a re-routing of the multivesicular bodies (MVBs)-containing 
endosomes to the cell surface (Figure 1.1) (27). It is worth mentioning that there is a third class 
of EVs, called apoptotic bodies (ABs), which are formed as a cell fragments during apoptosis 
(28). One of the main factors used to distinguish between the different classes of EVs, other than 
the mechanism underlying their biogenesis, is their size. Exosomes are the smallest type of EVs 
and are approximately 30-100nm in diameter, while MVs have the propensity to be much larger, 
ranging from 200nm-2µm. Lastly, apoptotic bodies are the largest class of EVs, with a diameter 
of 2-10µm (29).  
Formation and shedding of Microvesicles 
MVs are formed by the outward budding and fission of the plasma membrane and the 
subsequent release, or shedding, of the membrane-enclosed structure into the extracellular 
environment. MVs have been identified in the context of many different biological events, for 
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example, early studies drew comparisons between viral budding and MV formation, noting the 
similarity in requirements for rearrangement of structural proteins, packaging of select cargo, and 
deforming the plasma membrane for release of the virus from the cell (30). For example, some 
retroviruses will assemble Gag proteins and hijack the endosomal sorting complex required for 
transport (ESCRT), recruiting it to the plasma membrane along with the tumor susceptibility 
gene 101 (TSG101) (31). The assembly of the ESCRT complexes leads to the formation of a 
semispherical complex that distorts the curvature of the plasma membrane until the assembled 
particle pinches off from the surface of the cell (30).  
The mechanisms responsible for MV formation and shedding are still an active area of 
research, however, several studies have highlighted the importance of certain small GTPases and 
their ability to rearrange the actin cytoskeleton as key factors in the biogenesis of MVs. Both Ras 
homolog gene family member A (Rho A) and ADP-ribosylation factor 6 (Arf 6) have been 
shown to act as molecular switches in order to initiate changes in the actin cytoskeleton leading 
to MV formation (32, 33).  
Early studies in our laboratory directed at understanding how MVs are formed and 
mediate biological outcomes involved the detection of large (between 200nm-2.0µm) vesicular 
structures decorating the surfaces of cancer cells as detected by immunofluorescence using an 
antibody against tissue transglutaminase (tTG) (32). tTG is a crosslinking enzyme that has an 
elevated expression in several cancers and has been associated with chemoresistance and cell 
growth. The vesicles could also be visualized as ring-like structures on the surfaces of cells 
stained with rhodamine-conjugated phalloidin to detect filamentous actin (F-actin). Interestingly, 
MVs could be consistently detected on the highly aggressive MDAMB-231 breast cancer cell 
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line and the U87 glioblastoma cell line. However, MV formation in the HeLa cervical carcinoma 
cell line required the addition of epidermal growth factor (EGF). 
Discovering that MV biogenesis in HeLa cells was increased by EGF stimulation 
provided us with an opportunity to determine what might be functioning downstream of the EGF 
receptor (EGFR) to mediate this effect. Because MVs budding from the cell surface are likely to 
cause cytoskeletal rearrangements, proteins known to be activated by growth factor stimulation 
and regulate the actin cytoskeleton were investigated. The Rho family is a part of the larger Ras 
superfamily of small GTPases and includes a number of members, such as, RhoA, Rac, and 
Cdc42. Each of these small GTPases are activated by the EGFR and are known to mediate 
cytoskeletal rearrangements (34, 35). For example, RhoA has been shown to the activate Rho-
associated coiled-coiled forming kinase (ROCK), which then can phosphorylate the myosin-
binding subunit of myosin phosphatase to inactivate it, leading to actin assembly. The RhoA-
ROCK signaling axis can also influence the cytoskeleton by activating the mammalian homolog 
of Drosophila diaphanous (mDia), a formin molecule that promotes actin nucleation (36-38). 
Other members of the Rho family include Rac and Cdc42 to regulate cytoskeletal changes (39, 
40). Rac interacts with Arp2/3 to create a network of branched actin filaments for the formation 
of lamellipodia on the leading edge of a cell for migration (41). Cdc42 interacts with p21-
activated protein kinase (PAK) to induce the formation of filopodia, actin-dependent membrane 
protrusions involved in migration (40, 42).   
HA-tagged activated forms of Rac (Rac F28L), Cdc42 (Cdc42 F28L), or RhoA (RhoA 
F30L) were ectopically expressed in HeLa cells, and then cells were immunostained with tTG 
and HA antibodies to detect any MVs that were potentially forming on the surface of the 
transfected cells. Interestingly, only the HeLa cells expressing the activated form of RhoA were 
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found to have MVs on their surfaces. Consistent with this finding, knocking down RhoA 
expression in HeLa cells using a siRNA that specifically targeted this small GTPase were no 
longer able to form MVs in response to treatment with EGF. The study then went on to delineate 
the RhoA-mediated signaling pathway that was important for generating MVs in these cells. The 
pathway included the sequential activation of the kinases ROCK-1 and ROCK-2 and then Lim 
Kinase (LIMK) (37). LIMK, in turn phosphorylates cofilin on serine 3, which inhibits its actin 
filament severing activity (Figure 1.2) (43). Inhibiting cofilin activity at the sites of MV budding 
allows for the necessary changes to the actin cytoskeleton to occur (i.e. the formation of the 
characteristic actin rings seen in MVs from cancer cells) such that MVs are formed and release 
from a cell. Notably, if any component of this signaling pathway is inhibited, for example by 
using the ROCK inhibitor Y-27632, or by knocking down LIMK, the cell is no longer able to 
generate actin-based MVs (32).  
 Another study demonstrating the importance of a small GTPase in MV biogenesis came 
from the D'Souza-Schorey laboratory. In this case, they discovered that the Arf6 GTPase played 
an essential role in MV biogenesis (33) (Figure 1.3). Arf6 had been previously implicated in 
regulating the changes that need to occur to the actin cytoskeleton in order to turnover 
invadopodia (44). Invadopodia are actin-dependent protrusions of the plasma membrane 
involved in degradation of the extracellular matrix in cancer cell migration (45). However in this 
study, they showed that Arf6 could also influence MV formation. Whether Arf6 activity 
promoted invadopodia turnover or MV release was dependent on the stiffness of the surrounding 
extracellular matrix. In order to investigate this further, the group took advantage of an activated 
form of Arf6 (Arf6-Q67L), and a dominant-negative form of Arf6 (Arf6-T27N), to investigate 
the role that this small GTPase may play in MV biogenesis. Interestingly, they found that the 
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expression of the dominant-negative form of Arf6 lead to an increase in the amount of MVs that 
could be detected on the surfaces of the transfected cells, but an overall reduction in the amount 
of MVs released or shed by these cells into their media. Conversely, the expression of the 
activated mutant form of Arf6 led to fewer MVs on the surfaces of the cells, and an increase in 
the amount found in the media. This suggested that Arf6 activation is specifically required for 
the release of MVs from cells, rather than for their initial formation. The authors then went on to 
determine the signaling pathway through which ARF6 mediates its effects. Specifically, they 
found that Arf6 acts by signaling through phospholipase D (PLD) to activate extracellular signal-
regulated kinase (ERK) (44, 46, 47). Phosphorylated ERK then activates myosin light-chain 
kinase (MLCK) to promote contraction of actin-based structures that form at the neck between 
the surface of the cell and the emerging MV. Ultimately, the neck continues to get smaller to the 
point that membrane fission occurs and the MV is released into the extracellular environment. 
Consistent with this finding, inhibiting ERK activation lead to the buildup of MVs along the 
surfaces of cells expressing an inactive form of Arf6 (48, 49).  
 In addition to the roles that proteins play in the formation and shedding of MVs, several 
studies have also focused on how changes in the lipid composition of the plasma membrane also 
influence this process. One of the best examples of this can be seen when considering the 
asymmetrical distribution of phosphadidylserine (PS) that occurs in MVs (50). PS is normally 
maintained in the inner leaflet of the plasma membrane by ATP-dependent flippases. However, 
as MVs are budding from the surface of cells, it is characteristic for PS to become enriched on 
the outer surface of the membrane due to the activity of the lipid transporter scramblase (51, 52). 
The localization of PS to the outer leaflet of MVs has several potential functional consequences 
including, promoting the outward curvature of the plasma membrane and detachment of the 
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underlying cytoskeleton to promote MV shedding (53, 54). As will be discussed later, PS on the 
outer surface of MVs also plays a role in the ability of MVs to dock onto recipient cells. 
MV biogenesis has been associated with lipid rafts, a specialized microdomain of the 
plasma membrane that acts to compartmentalize cellular processes and serves as a center for 
assembly of signaling complexes (55). Lipid rafts are enriched with a specific set of proteins, 
glycosphingolipids, and cholesterol and are thought to be the site of MV biogenesis (56). MVs 
are enriched in cholesterol, and when cholesterol levels were depleted in cells due to treatment 
with MβCD (a reagent that removes cholesterol from membranes), MV generation by the 
monocytic cell line THP-1 was reduced (56, 57). It has also been shown that flotillin, a lipid raft 
marker, is also expressed in MVs, further suggesting that MVs form at sites of lipid rafts (58, 
59).  
 
Formation and shedding of exosomes   
 Exosomes are the class of EVs that are typically in the size range of 30-100nm in 
diameter (60). They are distinct from MVs in how they are formed (27). There has also been a 
good amount of discussion in the field recently regarding exactly what constitutes an exosome 
versus a MV; however, here I am referring to EVs shed by cells as a result of the re-routing of 
multivesicular bodies (MVBs) (also known as the multivesicular endosome (MVE)) from the 
lysosome to the plasma membrane (31). The MVB then fuses with the plasma membrane and 
releases its contents (endosomes) into the extracellular environment, at which point they are 
referred to as exosomes (Figure 1.1). The mechanisms involved in the formation of exosomes, 
are more established, compared to MVs. 
13
  The formation of MVBs begins as the early endosome is generated by the inward 
budding of the plasma membrane (Figure 1.4) (61). ESCRT-0 recognizes phosphatidylinositol 3-
phosphate on the membrane of the endosome and initiates the assembly of the ESCRT 
complexes for the formation of intraluminal vesicles (ILVs) within the endosome (62). ESCRT-0 
subunits contain binding motifs for ubiquitin, enabling the enrichment of cargo within the ILV 
(63). ESCRT-0 is also required for the recruitment of ESCRT-1 (64, 65). The ESCRT-I complex 
includes the protein TSG101, which acts as a link between ESCRT-0 and ESCRT-II, as well as 
engages cargo at the endosome mediating its sorting into MVBs through the formation of 
intraluminal vesicles (66). ESCRT-II promotes the interaction between the ESCRT complex and 
the endosomal membrane and plays a critical role in initiating ESCRT-III complex formation 
(67, 68).  
While ESCRT-0, I, and II are responsible for initiating complex formation and cargo 
recruitment, it is ESCRT-III that is responsible for deforming the endosomal membrane for cargo 
sequestration into ILVs (69). ESCRT-III is composed of 4 subunits known as charged 
multivesicular body proteins (CHMPs) in mammalian systems (70). ESCRT-III exists in an auto-
inhibited state in the cytoplasm, but upon interacting with the ESCRT-II subunit Vps25, the 
ESCRT-III subunit Snf-7 undergoes a conformational change and assembles into a filament that 
interacts with the endosomal membrane (71). Upon interacting with Vps4, Snf-7 induces the 
curvature and scission responsible for formation of the ILV (72). Another protein required for 
this process is Bro1/Alix (BCK1-like resistance to osmotic shock protein/ apoptosis-linked gene-
2 interacting protein X), which aids in the stabilization of Snf-7 and recruits the de-ubiquitinating 
enzyme Doa4 for processing ILV cargo (73).  
14
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Classically, MVBs go on to fuse with a lysosome to degrade the ILVs and their cargo. 
However studies are starting to reveal that some MVBs can instead be re-directed to the plasma 
membrane for release of ILVs as exosomes in the extracellular space (31). The mechanisms 
regulating this process have been discovered. For example, Rabs, monomeric GTPases and 
members of the Ras superfamily, have been shown to be important for promoting the association 
of MVBs with the plasma membrane. Rab GTPases are best known for their roles in directing 
the localization of membrane-bound organelles and for intracellular vesicle transport (74). 
Recently, Rab27a and Rab27b were shown to be necessary for the proper targeting of the MVB 
to the plasma membrane, both being required for the secretion of exosomes by HeLa cervical 
carcinoma cells (75). Moreover, the ectopic expression of a dominant-negative form of Rab35 in 
HeLa cells led to the accumulation of intracellular endosomal vesicles and impaired exosome 
secretion. The GTP-bound form of Rab35 was found to localize to the plasma membrane, 
suggesting that it can play a role in MVB docking or tethering to the plasma membrane (76). 
Yet, another study found that Rab11 regulates MVB targeting to the plasma membrane, 
culminating in a calcium-dependent fusion event (77). Overall, the release of exosomes is a 
highly regulated process that can occur in most cell types.  
Apoptotic bodies 
Apoptotic bodies are the largest class of vesicles, ranging from 2-10µm in diameter and 
are formed by cells undergoing programmed cell death (28, 78). The defining differences 
between apoptotic bodies and other types of EVs (exosomes and MVs) are that their cargo is 
non-specifically sorted into them and apoptotic bodies can contain entire organelles (78, 79). The 
formation of apoptotic bodies is thought to help break down dying cells into fragments that can 
17
be more efficiently phagocytosed by macrophages, while avoiding rupturing the cell and 
releasing immunostimulatory molecules, as occurs in necrotic cells (80). This prevents the 
exposure of “self” proteins and DNA to immune cells, protecting against the initiation of an 
auto-immune response (81, 82).  
 
Isolation of MVs and exosomes 
The challenging questions in the field of EVs regarding the differences between MVs and 
exosomes in different biological processes are made even more difficult due to the lack of 
standardized nomenclature and isolation procedures for EVs. It is becoming increasingly clear 
that some laboratories are isolating MVs but calling them exosomes and vise versa. Other groups 
are simply isolating both MVs and exosomes together (referred to as “batch preparations”). This 
has lead to confusion and without standardizing the nomenclature and isolation procedures, 
advances in the field are impeded. Our laboratory has adopted the most widely accepted 
approach for distinguishing the different classes of vesicles, specifically, that microvesicles are 
larger and bud directly from the plasma membrane, while exosomes are smaller and are formed 
from a re-routing of the endosomal pathway. One of the areas being developed that will certainly 
help eliminate these concerns is the identification of markers for the different classes of EVs.  
 Several approaches for collecting EVs from cell culture media have been developed 
including those involving precipitation, membrane filtration, gel filtration, differential 
ultracentrifugation, and affinity purification (28, 83-86). There are benefits and drawbacks for 
each approach. For example, the precipitation-based method results in the non-specific 
aggregation of all vesicles and macromolecular structures, and although it is a relatively easy 
procedure to carry out, the vesicles they isolate have been shown to be less bioactive, and have 
18
different particle sizes, compared to other EV isolation procedures (87). Gel filtration, also 
known as size exclusion chromatography has been effectively used for the purification of nucleic 
acids, proteins, peptides, and lipids by passing samples through a column of porous beads. 
However, EVs and high-density lipoproteins (HDL) have a similar density and were found to co-
isolate, and further studies are required to determine the effects of bead type and buffer 
composition for the fractionation of EVs using gel filtration (88). Differential centrifugation is 
the most prevalent method of isolating EVs. Generally it involves a low-speed centrifugation 
step (300xg for 5-30 minutes) to remove cells and cellular debris, a high-speed centrifugation 
(10,000-20,000xg for 30 minutes), and finally an ultracentrifugation step (100,000xg for 1-18 
hours) (89). It was determined that longer spin times in the ultracentrifugation step led to greater 
yields of EVs, however, it also caused the aggregation of vesicles, decreasing their functionality 
in biological assays. Additionally, the vesicle populations in the 10,000xg and 100,000xg 
fractions were found to be heterogeneous in size and vary significantly depending on the type of 
rotor, centrifuge tube, and centrifuge model (83, 89). 
A method for separating vesicles by size involves the use of membrane filters with 
successively smaller pore sizes, resulting in a population of vesicles with improved size 
homogeneity while avoiding high g-forces and precipitants that may be present with the use of 
other methods (83). Limitations of the membrane filter method include clogging of the filter, 
potentially disrupting the vesicles due to sheer force, and the possibility for different forms of 
vesicles to be of a similar size, however, this limitations can be overcome by proper sample 
handling techniques. 
For the purposes of separating out different fractions of EVs from a homogeneous cell 
population, our laboratory developed an approach that combines differential centrifugation and 
19
membrane filtration (Figure 1.5) (90). Cell culture supernatant, also known as conditioned 
media, was collected from serum starved cells and subjected to two consecutive centrifugations 
at 300×g to clarify the media of cells and large cellular debris. Due to the presence of EVs in the 
media supplemented with fetal bovine serum (FBS), it is vital to use serum depleted of EVs, or 
preferably to use serum-free media for EV collection, when possible (91).  
The partially clarified media was filtered using a Steriflip PVDF filter with a 0.22 µm 
pore size and extensively rinsed to remove soluble factors with special care taken to avoid 
clogging the filter, or subjecting the vesicles to physical stress. The EVs retained by the filter are 
considered MVs, as they represent EVs that are 200 nM and larger. The larger EVs retained by 
the filter could be resuspended in medium for use in cell-based (biological) assays, or lysed 
directly off the filter membrane to generate MV lysates. Exosomes were isolated from the 
conditioned medium that flowed-through the 0.22 µm Steriflip filter (i.e. vesicles smaller than 
220 nm) by centrifugation at 100,000xg for 2 hours, or alternatively, they were collected from 
the flow-though using a filter with a 100,000 kDa size cut-off. EV fractions were then confirmed 
using nanoparticle tracking analysis (NTA) to determine the sizes and amount of EVs in a given 
preparation, as well as Western blot analysis with EV-specific markers. This method has been 
used to reliably separate exosomes and MVs by size, while removing cells, debris, and apoptotic 
bodies.  
To follow the fate of the isolated EVs and demonstrate the transfer of EV cargo to the 
cytoplasm of a donor cell, several biochemical assays have been developed. A chemical 
compound such as a carboxyfluorescein succinimidyl ester (CFSE) or 5(6)-carboxyfluorescein 
diacetate (CFDA) can be incorporated into EVs. EVs containing these chemical compounds are 
then added to the culture medium of recipient cells. If the CFSE or CFDA is transferred to the 
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recipient cell, the cell will fluoresce due to the esterification of the chemical compounds. This 
makes it possible to distinguish between EVs that fuse with the recipient cell to transfer cargo, 
and EVs that dock on the surface of the recipient cell without fusing (92, 93).  
EV cargo 
The importance of EVs for diagnostic purposes, and for their ability to perform diverse 
biological functions, is dependent on the cargo they contain. The contents of EVs are often 
representative of their cell of origin and includes cell surface receptor tyrosine kinases, cytosolic 
signaling proteins, metabolic proteins, metalloproteases (MMPs), nuclear proteins, messenger 
RNA transcripts, micro-RNAs, and cytoskeletal components (16, 19, 33, 94-99). A great effort is 
being made to catalog the various protein, lipid, and nucleic acid content of EVs in order to 
identify markers that can be used to identify each class of EV (i.e. MV versus exosome), as well 
as EVs shed by diseased cells (Figure 1.6). Although there have been challenges in 
demonstrating cargo specificity between different classes of EVs, there is evidence of cargo 
found preferentially expressed in one class of EV over the other (8).  
RNA as EV cargo 
Perhaps the most investigated types of EV cargo are RNA transcripts and miRNAs, 
which are sometimes referred to as exRNAs or evRNAs. RNA can be isolated from EVs from 
nearly all tested biofluids, and have garnered great interest due to their ability to alter protein 
expression in recipient cells, and for their potential use in the clinics as biomarkers for disease, 
and even as potential therapeutic agents (100, 101).  
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Mechanisms that target certain RNA species to EVs have been uncovered by comparing 
the mRNAs expressed by cancer cells and the EVs that these cells generate. It was found that 
many mRNAs are highly enriched in EVs compared to their levels in the cells, indicating that the 
trafficking of mRNAs into EVs is a highly regulated process (16, 20). For example, a landmark 
study in the EV field focused on identifying the most abundant mRNA transcripts in MVs shed 
by glioblastoma cells (16). The most abundant mRNAs detected belonged in ontologies related 
to tumor growth, including angiogenesis, cell proliferation, and cell migration. The authors went 
on to show that mRNAs delivered to recipient cells via MVs could be translated and generate a 
functional protein using a luciferase reporter sequence. The researchers demonstrated that tumor-
specific RNA sequences, such as epidermal growth factor receptor variant type III (EGFRvIII), 
were found in MVs collected from the serum of glioblastoma patients, highlighting the potential 
for mRNA sequences such as EGFRvIII to be used as biomarkers.  
A large effort is being made to identify specific sequences contained within the RNA 
transcripts that are important for targeting them to EVs. In fact, studies have identified specific 
cis-acting RNA elements common to at least some of the mRNAs detected in EVs (102). These 
~25 nucleotide length sequences are sometimes referred to as “zip code”-like sequences, and are 
found in the 3’-untranslated region (3’UTR). When these “zip codes” were incorporated into the 
3’UTR of a reporter mRNA, the levels of the receptor RNA detected in the EVs derived from the 
cells were increased (103). More importantly, mRNA cargo delivered by EVs can be translated 
into their corresponding proteins by the recipient cell, a process that is inhibited by heat 
inactivation or prolonged RNAse treatment of the EVs before culturing them with recipient cells 
(98).  
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The miRNA content of EVs is a prominent component of secreted RNAs and can 
strongly influence the phenotype of recipient cells by altering gene expression (20, 104). The 
precise mechanism by which miRNAs are selectively trafficked into EVs has yet to be 
confirmed. However, several recent findings have suggested that proteins that bind to miRNAs 
might be important for their recruitment to exosomes (105). A good example of this involves 
Argonaute 2 (Ago2), a component of the RNA-induced silencing complex (RISC). Ago2 is an 
essential component of the miRNA-mediated degradation of mRNA and has been detected in 
extracellular vesicles, specifically exosomes, while in complex with miRNA (106, 107).  Ago2 
associates with MVBs during the formation of intraluminal vesicles and aids in the sorting of 
miRNA into the endosome (108). Over activation of KRAS in cancer cells has been shown to 
increase Ago2 activation, altering the miRNA content of exosomes (97, 109, 110). Mutant 
KRAS was shown to act through MEK I/II by phosphorylating Ago2 on S387 to inhibit the 
association of Ago2-miRNA complexes with MVBs, and altering the miRNA content of 
exosomes (109).  
Interestingly, RNA species found to be enriched in EVs relative to cellular RNA includes 
a large variety of small non-coding RNA species, long non-coding RNA, repeat sequences, 
structural RNAs, transfer RNA (tRNA), and Y-RNA (bound to ribonuclear complexes) (95). The 
enrichment of non-coding RNA in EVs introduces a wider range of biological effects that could 
be mediated by EV RNA than just transferring messages.  
MV protein cargo sorting 
Despite the advancements in our understanding of MV biogenesis, and how they 
contribute to various biological processes and disease states, there are still several major 
27
questions regarding how MVs are loaded with cargo. There are a few cases where this question 
is starting to be addressed. For example, it has been demonstrated that for amoeboid-like 
invasive tumor cell lines, v-SNARE-vesicle associated membrane protein (VAMP3), potentially 
regulates the loading of cargo into MVs (111). VAMP3 is a SNARE protein known to play a role 
in intracellular membrane fusion and the subcellular localization of proteins such as matrix 
metalloproteases (MMPs), proteins critical for remodeling the extracellular matrix (112, 113). 
VAMP3 and a specific MMP known as MT1-MMP co-localize at sites of active MV formation, 
and can be detected in shed MVs. However, when VAMP3 is depleted from an invasive 
melanoma cell line, LOX, by shRNA, MT1-MMP is no longer detected at sites of MV 
formation, nor is it detected in the MVs that the cells release (111). Decreasing VAMP3 
expression and subsequent loss of MT1-MMP as MV cargo, decreased the efficiency with which 
cells are able to migrate through the extracellular matrix. Interestingly, MVs isolated from 
ovarian cancer patients also contained VAMP3 and MT1-MMP, and were capable of matrix 
degradation. Thus, the inclusion of MMP in MVs generated by cancer cells appears to play an 
important role in their ability to migrate and invade through the tumor microenvironment. 
  
Exosome protein cargo sorting 
 Incorporation of protein cargo into ESCRT-dependent exosomes is a slightly better 
understood event, and several of the complexes involved in the formation of exosomes are also 
involved in incorporating cargo. Classically, ubiquitylation of membrane proteins triggers their 
sorting into ILVs by binding to the ESCRT-0, I, and II complexes, which have several distinct 
ubiquitin-binding motifs (67, 114, 115). An additional mechanism involves the ESCRT-III 
adaptor protein Alix binding to the C terminus of Snf7; and loss of Alix affects cargo sorting 
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(116). Alix has also been shown to interact with syndecans and syntenin to segretate exosome 
cargo into ILVs; specifically, syntenin overexpression stimulated exosomal release of FGFRs 
(117).  
Certain protein modifications can influence the localization of proteins to exosomes. 
Adding a membrane-targeting 10-amino acid acyl tag to the N-terminus of the yeast cytoplasmic 
protein TyA-GFP, targeted it to endosome-like domains of the plasma membrane and resulted in 
its efficient incorporation into endosomes (118). This also resulted in its enrichment in the 
exosomes secreted by these cells. A subset of early endosomes are thought to originate in lipid 
raft domains, areas of the plasma membrane enriched with cholesterol and 
glycosylphosphatidylinositol (GPI)-anchored proteins (119). Proteins with a GPI tag such as 
CD55 and CD59 are enriched within exosomes, and adding a GPI tag to proteins that do not 
normally have one increased their localization to exosomes (120). 
  Although addition of a membrane-targeting domain has been shown to increase the 
localization of proteins to exosomes, our laboratory and others have shown that many proteins 
lacking these membrane-targeting modifications can also be found in exosomes. For example, 
the small anti-apoptotic protein survivin is primarily expressed in the nucleus and mitochondria. 
However, exposing cancer cells to various stresses, for example, non-lethal doses of ionizing 
radiation, can lead to an increase in the levels of survivin detected in exosomes generated by the 
cells (121, 122). Additionally, I have discovered that the disruption of microtubule dynamics 
using the chemotherapeutic drugs nocodazole or paclitaxel leads to a significant enrichment of 
survivin in exosomes without changing the total survivin detected within the cells.  
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EVs interacting with recipient cells 
Several different mechanisms have been suggested for how EVs interact with recipient 
cell including juxtacrine signaling, endocytosis, phagocytosis, or direct membrane fusion (Figure 
1.7) (7, 123). This transfer event can be observed by labeling EVs with a fluorescent lipid 
membrane dye and detecting the fluorescent signal being distributed throughout the plasma 
membrane of a cell treated with labeled EVs (124). Many studies have shown that there is either 
a direct fusion of the EV membrane with the plasma membrane of the recipient cell, or that the 
EV is endocytosed and the EV fuses with the endosomal membrane to deposit cargo into the 
cytoplasm of the recipient cell (92).  
The majority of experimental evidence suggests that EVs are taken up by cells via 
endocytosis and enclosed within endosomal compartments (125, 126). This is thought to be an 
active process, since it can be nearly entirely blocked if the recipient cells are incubated at 4°C, 
fixed with paraformaldehyde, or treated with Cytochalasin D to depolymerize actin filaments and 
inhibit endocytic pathways (127, 128). One form of endocytosis involves clathrin-coated 
vesicles. Clathrin is able to deform the membrane into a bud to form an intracellular vesicle 
which undergoes subsequent clathrin un-coating before fusing with the endosome and depositing 
its contents into the cytoplasm of the recipient cell (129). Clathrin-mediated endocytosis can be 
inhibited by treating cells with chlorpromazine, and a study has shown that treating ovarian 
cancer cells with this inhibitor reduces their ability to take up EVs (130, 131). Another form of 
endocytosis involves the formation of caveolae, cave-like pits on areas of the plasma membrane 
rich in cholesterol (132). Some studies suggest that caveolae inhibition will impair a cell’s ability 
to uptake EVs; however, additional studies have shown that mouse embryonic fibroblasts 
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derived from CAV1 knock out animals lead to an increase in EV uptake, suggesting that 
different cell types may use distinct mechanisms to uptake EVs (126).  
Another form of endocytosis is macropinocytosis and involves the formation of 
membrane ruffles that invaginate to internalize an area of extracellular fluid (132, 133). The 
GTPase Rac1 is a major regulator of macropinocytosis, however, actin and cholesterol are also 
required for this process to occur (134). It is generally thought that macropinocytosis is 
stimulated by the activation of phosphatidylinositol-3-kinase (PI3K), Ras, and c-Src activity 
(124, 132). Macropinocytosis does not require direct interaction between the plasma membrane 
and the internalized material (i.e. EVs); however, phagocytosis is a receptor-mediated 
internalization of material from the extracellular environment (132, 133, 135). Macrophages are 
well known for their ability to phagocytose, and frequently utilize this process to internalize 
larger particles. However, small exosomes derived from leukemia cells have been reported to be 
phagocytosed by macrophages in an actin- and PI3K-dependent mechanism (135). Interaction 
with EVs at the cell surface is necessary for their phagocytosis as proteinase K treatment of EVs 
significantly reduces their uptake (131).  
The presentation of phosphatidylserine (PS) on the outer leaflet of EV membranes also 
plays a role in their uptake, especially by phagocytosis (136). A highly metastatic melanoma cell 
line, B16F10, produces large quantities of MVs with PS on their outer membrane. These MVs 
were found to be extremely potent in enhancing the metastatic potential of cells injected in mice, 
a phenomenon reversed by treating the EVs with annexin V (52). Annexin V is a phospholipid 
binding protein that specifically binds to PS. Thus, pretreatment of MVs with annexin V prevents 
a recipient cell from binding to PS on the EV membranes and triggering endocytosis of the EVs. 
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As a result of this finding, annexin V has become commonly used as a way to block EV uptake 
by recipient cells (19, 125, 135).  
It is also possible for EVs to influence recipient cells without requiring internalization of 
the vesicles. Multiple studies have found that proteins expressed on the surface of EVs are 
sufficient to bind to receptors expressed on the recipient cells and activate signaling events. For 
example, exosomes shed by the cells making up the outer layer of a blastocyst-stage embryo 
called trophoblasts, can induce synthesis of pro-inflammatory cytokines by macrophages. 
Importantly, these effects were not blocked by inhibitors that prevented EV uptake (e.g. annexin 
V), suggesting the internalization of the exosomes was not required to influence the recipient 
cell. However the exosome-dependent signals were blocked by using an RGD peptide, which 
specifically inhibits the ability of the extracellular matrix protein fibronectin to function as a 
ligand and interact with and activate α5β1 integrin receptors expressed on the recipient 
macrophage. This signifies that the exosome docking at the plasma membrane of the recipient 
cell was sufficient to induce changes within the macrophage (137). Another study performed in 
our laboratory found that MVs shed by mouse embryonic stem (ES) cells were coated with both 
fibronectin and laminin, which binds to the integrins and laminin receptors on the surface of 
trophoblasts. These interactions activate JNK and FAK signaling in the trophoblast and promote 
their ability to migrate, an essential step for embryo implantation (90).  
Another study from our laboratory highlighted the importance of MV-associated 
fibronectin in the context of cancer progression (94). MVs derived from the highly aggressive 
MDAMB-231 breast cancer cells and U87 glioma cells were shown to be capable of transiently 
transforming normal (non-transformed) fibroblasts due to the MV cargo tissue transglutaminase 
(tTG), a protein crosslinking enzyme, and fibronectin. The study found that tTG cross-links 
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fibronectin located on the surface of MVs. The cross-linked form of fibronectin was then able to 
engage integrins on recipient cells and strongly induce signaling events (i.e. activate JNK, PI3K, 
and ERK) that impacted their function.  
EVs and tumor progression 
Tumor initiation and progression requires continuous communication between cancer 
cells and the cells within the local microenvironment (138). EVs are now recognized as an 
important mediator of this cross-talk (139). Specifically, EVs derived from highly aggressive 
forms of cancer cells have been shown to activate fibroblasts, stimulate tumor angiogenesis, alter 
immune responses, and aid in the development of a pre-metastatic niche (Figure 1.8) (94, 140, 
141).  
The effects of EVs on cell growth and survival 
As mentioned previously, the EV-mediated transfer of RNA species between cells has 
been demonstrated to play a major role in changing the behavior of recipient cells (16). In order 
to understand the ability of EVs derived from primary glioblastoma cell lines to manipulate 
surrounding cells, one study focused on the most abundant miRNA identified in EVs, miR-21 
(142). Incubating mouse microglia cells with EVs derived from these glioblastoma cell lines 
alters the cytokine production to promote the growth and survival of the cancer cells. The 
researchers demonstrated the EV-dependent transfer of miR-21 from glioblastoma cells to 
recipient microglia cells. miR-21 has been shown to play a role in regulating cell survival, and in 
fact, there was a 40% increase in cell viability over the course of 7 days when microglia cells 
were incubated with EVs derived from glioblastoma cells.  
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 One of the original studies linking EVs to cancer progression investigated how EVs 
propagate the oncogenic phenotype exhibited by highly aggressive human brain tumors known 
as gliomas (19). These tumors were shown to shed EVs that contain a highly oncogenic form of 
the epidermal growth factor receptor (EGFR) called EGFR variant III (EGFRvIII). This mutant 
form of the receptor arises from an in-frame deletion event and activates signaling events (i.e. 
activation of ERK and PI3K) that simulate cell growth and survival.  
EGFRvIII is only expressed in a low number of cells within a glioma tumor (143). 
However the influence of the mutant receptor within the tumor is pervasive, suggesting that 
EGFRvIII is shared between glioma cells by intercellular transfer via EVs. The researchers 
observed that when the glioma cell line U373 stably expressed EGFRvIII, these cells shed more 
EVs, and these EVs contained EGFRvIII. This may be because oncogenic receptors tend to 
localize within specific regions of the plasma membrane, like lipid rafts, from which MVs have 
been suggested to originate from (56). When injected into nude mice, the EGFRvIII expressing 
cells were readily able to form tumors unlike the parental control cells. Additionally the blood 
serum collected from EGFRvIII tumor-bearing mice contained vesicles that could be isolated and 
were found to contain the EGFRvIII mutant receptor, demonstrating the systemic release of EVs 
from a tumor.   
The consequences of transferring MVs derived from EGFRvIII-expressing glioma cells 
to recipient parental U373 cells were examined (19). First, a GFP-tagged version of EGFRvIII 
was expressed in the donor cells to demonstrate the uptake of GFP-EGFRvIII-positive EVs by 
recipient cells. Indeed, the resulting fluorescent images taken of the cells treated with these EVs 
showed that the fluorescent signal could be detected along the plasma membrane of the recipient 
cells. The EV-mediated transfer of the EGFRvIII to the recipient glioma cells stimulated Erk1/2 
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and Akt activation and these signals could be blocked by treating the EVs with an EGFR 
inhibitor, or with annexin V to block EV uptake. The presence of EGFRvIII ultimately resulted 
in tumor growth and survival.  
EVs and tumor angiogenesis 
Tumor progression requires the recruitment and formation of new blood vessels for the 
tumor mass to grow beyond the diffusion limit of the existing vasculature. A potent mediator of 
angiogenesis is the vascular endothelial growth factor (VEGF). When VEGF is secreted it is 
recognized by VEGF receptors on vascular endothelial cells and leads to their activation for the 
formation of new blood vessels. As mentioned previously, there is an oncogenic form of the 
EGFR called EGFRvIII, and expression of this mutant receptor can lead to the increased 
secretion of vascular endothelial growth factor (VEGF) (144). In fact, when endothelial cells 
were cultured with EVs derived from EGFRvIII-expressing cells, the recipient cells exhibited a 
marked increase in the production of VEGF for the autocrine activation of angiogenesis (15).  
Hypoxia is known to be a trigger for angiogenesis within a tumor microenvironment and 
one study found that hypoxia was sufficient to alter the cargo of EVs derived from an aggressive 
glioblastoma (GBM) brain tumor to a pro-angiogenic state (145). GBM cells grown in a hypoxic 
environment generate EVs that are enriched with factors related to tumor development including 
adrenomedullin (ADM), lysyl oxidase (LOX), IGF binding protein (IGFPB) 3, inhibitor of DNA 
binding 2, B-cell lymphoma (BCL)2/adenovirus E18 19-kDa interacting protein 3 (BNIP3), N-
myelocytomatosis viral related oncogene (myc) downstream regulated 1 (NDRG1), procollagen-
lysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2), and plasminogen activator inhibitor-1 (PAI1). 
Endothelial cells readily take up GBM EVs, and when hypoxic GBM EVs were compared to 
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EVs isolated from GBM cells grown in normoxic conditions, they were more potent at inducing 
microvascular sprouting, and are able to induce tubulogenesis in vitro. To examine the 
differences in vivo, EVs derived from normoxic and hypoxic GBMs were injected in a mouse 
tumor xenograft model. Interestingly, after the tumors were grown for 5 weeks, there was a 
substantial increase in tumor vascularization and almost three-fold increase in tumor volume.  
 
Migration 
 Tumor cell migration and invasion require a unique interaction between the cell and the 
microenvironment, and is essential for tumor cell dissemination and metastasis (146). The role of 
EVs in reshaping the tumor microenvironment in ways that promote migration and invasion have 
been attracting more and more attention (33, 53, 58, 147, 148).  
 As mentioned previously in this chapter, Arf6 can regulate the shedding (release) of the 
class of EVs known as MVs from cells. In this same study, the authors also found that these 
vesicles played a key role in the cancer cell’s ability to degrade extracellular matrix and for 
generating paths for the cancer cells to migrate and invade (33). These MVs are dependent on 
RhoA activity and are selectively enriched with cargo that promotes invasive activities, including 
matrix metalloproteases (MMPs) that efficiently deform less rigid environments. The MV-
mediated release of MMPs, such as MMP-2, and MMP-9 has been shown to be a critical event in 
migration and invasion, leading to higher rates of angiogenesis and metastasis (33, 44, 149). 
 The class of EVs known as exosomes has also been implicated in the directional 
migration of cancer cells. It had been shown previously that exosomes play a role in cell invasion 
and migration where detachment of adherent cells would induce a rapid release of exosomes that 
mediate adhesion to extracellular matrix proteins (150). A role for exosomes in the directional 
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migration of cancer cells in vivo has also recently been shown (151). Fluorescently labeled 
HT1080 fibrosarcoma cells were injected into chick embryos, which rapidly formed tumors that 
exhibited a significant amount of invasive activity. HT1080 cells were then treated with short 
hairpin RNAs (shRNAs) that specifically targeted synaptotagmin-7 (Syt7) or Rab27a, two 
proteins that regulate the fusion event between MVBs and the plasma membrane. Thus, the down 
regulation of Syt7 and Rab27a expression significantly impaired the ability of these cancer cells 
to shed exosomes. When HT1080 cells depleted of Syt7 and Rab27a were injected into chick 
embryos, they again formed tumors, similar to the control cells. However, these cells had 
significantly shorter invasive fronts, revealing that fewer cells had migrated away from the tumor 
compared to control cells. Time-lapse images collected from injected control HT1080 cells 
showed that they exhibited directional cell migration (i.e. away from the tumor). On the other 
hand, those HT1080 cells incapable of generating exosomes frequently stop and change 
direction, as well as move more slowly.  
To investigate this phenomenon further, exosomes from the cancer cells were purified 
and then either added directly to the culture media, or were used to coat the surface of the dish. 
In both situations, migration of control HT1080 cells was increased further, however, the 
migration defect in the Rab27a-knock down cells was rescued only when the exosomes were 
coated to the surface of the culture plates. This suggests that the cells require exosomes at the site 
of adhesion formation in order to migrate properly through the matrix. Due to the fact that 
fibronectin was identified as a major exosomal cargo and is involved in the interaction between 
the cell and the extracellular matrix (137, 152, 153), the researchers went on to determine if 
fibronectin is involved in the observed exosome-mediated migratory effect. Tissue culture dishes 
were coated with either purified exosomes, or purified fibronectin, and both conditions were 
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sufficient to rescue the motility speed defect of Hrs-knock down HT1080 cells. To visualize 
exosomes in migrating cells, HT1080 cells expressing fluorescently-tagged forms of CD63 (an 
exosome marker) and paxillin (focal adhesion marker) were imaged by video microscopy. 
Interestingly, CD63 positive “trails” were seen behind migrating cells, and these deposits 
preceded adhesion formation. These exosomes present in the extracellular matrix are thought to 
act as pro-migratory tracks for the regulation of directional movement. In fact, recent studies in 
neutrophils have found that exosome trails laid down in the extracellular matrix also contain 
chemoattractants that lead to an increase in migration persistence and directionality while also 
recruiting neighboring neutrophils (154). 
 
Metastasis 
 Most cancer fatalities occur when the primary tumor spreads or metastasizes to other sites 
in the body. The influence of EVs on the prerequisites for metastasis, including tumor 
angiogenesis and increased cancer cell migration, has already been discussed. However, EVs can 
also directly participate in establishing a secondary site of tumor growth (5, 29, 53). There have 
been multiple reports highlighting how EVs promote metastatic spread by contributing to the 
formation of the pre-metastatic niche, a specialized microenvironment that is established at a 
distant site and increases the chances that cancer cell will settle and grow at this site (155).  
To investigate the role of EVs in metastasis, EVs derived from melanoma cells were 
injected into the tail vein of a mouse, tracked through the lymphatic system and were found to 
accumulate in the lymph nodes (156). The tumor-derived vesicles were more likely to localize to 
lymph nodes and recruit melanoma cells due to their pro-metastatic cargo including integrin αv, 
MAPK and TNF-α (157, 158). Using a similar melanoma model, it was shown that fluorescently 
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labeled exosomes derived from the highly malignant B16-F10 melanoma cell line could be 
detected throughout the blood stream of the animal within 5 minutes of being injected. Within 24 
hours of injection, the exosomes were localized to the lungs, bone marrow, liver, and spleen of 
the mice (common sites of melanoma metastasis), but were no longer detected in the circulation 
(159). Gene expression profiling of lung tissue after a tail vein injection of EVs revealed 130 
differentially expressed genes, many related to extracellular matrix remodeling, and heat-shock 
proteins S100a8 and S100a9, which have been implicated in the formation of the pre-metastatic 
niche (160).  
 The metastatic effects of EVs derived from a subpopulation of human renal cell 
carcinomas were also studied (161). This cell line was shown to be a subset of cells with tumor-
initiating properties expressing the mesenchymal stem cell marker CD105 (162). EVs collected 
from renal cancer cells sorted for CD105 were able to stimulate angiogenesis, apoptosis 
resistance, and the invasion of endothelial cells significantly more than CD105- renal cancer 
EVs. The EVs were then shown to play a role in priming the metastatic site. EVs were 
intravenously injected into mice for 5 days in a row, and on the sixth day, renal tumor cells were 
injected. Five weeks later, the liver, spleen, kidney, and lungs of the mice were recovered and 
analyzed for tumor formation. Metastases were detected only in the lungs isolated from mice 
injected with CD105+ EVs, while the mice injected with EV vehicle alone, with CD105- EVs, or 
with RNase-treated CD105+ EVs, lacked detectable metastases. The CD105+ EVs were shown 
to contain mRNA species for VEGFR1, VEGF, MMP9, and MMP2, and these EVs were capable 
of increasing expression of these proteins in lung endothelial cells. VEGF is a signaling factor 
that stimulates angiogenesis, while MMP proteins alter cell-cell and cell-extracellular matrix 
interactions necessary for recruiting of endothelial cells and establishing vasculature (163, 164). 
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 The idea that tumor-derived EVs can promote metastasis has recently been expanded to 
the notion that these EVs can predict metastasis. Tumor-derived exosomes have been shown to 
localize to specific sites of organotropic metastasis, dependent on the type of primary tumor 
(140, 159, 165). To determine if exosomal cargo was helping direct organ specificity, proteomics 
were performed on exosomes derived from several different tumor models that are known to 
metastasize to specific sites (166). The study revealed that specific integrins expressed on tumor-
derived exosomes, distinct from the tumor cell of origin, determined where the cancer 
metastasized. For example, exosomes carrying integrin αvβ5 specifically bound to Kupffer cells, 
mediating liver tropism, however, exosomes with integrin α6β4 and integrin α6β1 bound to lung 
fibroblasts and epithelial cells, governing lung tropism. Interestingly, the researchers were able 
to alter the site of metastasis of 1833-BoT, a MDAMB-231 cancer sub-line that metastasizes to 
the bone marrow by pre-injecting mice with exosomes derived from 4175-LuT, a MDAMB-231 
sub-line that was selected for metastasizing to the lung, causing a significant increase in the 
presence of 1833-BoT metastasis in the lung. The data correlated with the integrin profiles of 
EVs collected from cancer patients, suggesting plasma-derived EVs could be useful in predicting 
the metastatic potential of patient tumors.  
 
Chemotherapy resistance 
 The management of cancer includes surgery, radiotherapy, and chemotherapy. While 
advancements in patient care have been made, development of chemoresistance is a persistent 
problem faced by clinicians. The mechanisms behind therapy resistance are numerous and varied 
and can often be attributed to a small subpopulation of cancer cells that make up a tumor that are 
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inherently resistant to a given therapy. (167). In order to overcome resistance, a deeper 
understanding of the different mechanisms involved in drug resistance is needed. 
 EVs have been shown to contribute to chemotherapy resistance. For example, 
immunotherapy against the B-lymphocyte plasma membrane protein CD20 in malignant 
lymphoma has a wide range of responses in patients. It was determined that lymphoma cells 
were releasing exosomes that carried CD20, and binding the therapeutic anti-CD20 antibodies, 
decreased the effectiveness of the therapy (168). However, by combining the immunotherapy 
with pharmacological inhibition of exosome biogenesis targeting the lysosome-related organelle-
associated ATP-binding cassette (ABC) transporter A3 (ABCA3), there was a significant 
increase in the amount of lymphoma cell death.  
 EVs can also decrease drug efficiency by acting as a mechanism to remove the drug from 
the cell, as seen in human ovarian carcinoma cells treated with cisplatin (169). The researchers 
showed that cisplatin-resistance correlated with increased expression of lysosome associated 
proteins 1 and 2 (LAMP1 and LAMP2) and vesicle trafficking proteins in the resistant cells, and 
increased levels of cisplatin export transporters in the exosomes. This response led to an increase 
in the amount of exosomes generated, and a subsequent decrease in the levels of cisplatin within 
the cells. Another study showed that the rate of EV shedding also correlated with doxorubicin 
insensitivity in various cancer cell lines (170). Twenty-four hours after treating the cancer cells 
with fluorescent doxorubicin, the drug went from having a predominantly nuclear localization to 
being present in extracellular vesicles loosely associated with the plasma membrane. Shed 
vesicles isolated from conditioned media of treated cells were isolated and shown to contain the 
labeled drug in as little as 2 hours after treatment.  
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Concluding remarks 
 EVs are being aggressively pursued as a diagnostic indicator. EVs collected from the 
bloodstream of cancer patients are a frequent source, however they have also been studied in the 
context of other diseases and collected from other biological fluids including urine, saliva, and 
cerebral spinal fluid (171-174). Considering the prevalence and accessibility of EVs in biological 
samples, and because EV cargo reflects the cell of origin, there is understandable enthusiasm for 
the use of EVs for diagnosis and indicators of disease progression. In fact, exosomes have been 
proposed as a non-invasive screening tool for pancreatic cancer, a disease notorious for being 
diagnosed in late stages. Glypican-1 was found to be specifically enriched in cancer cell-derived 
exosomes, and in the serum of patients with pancreatic cancer with high specificity and 
sensitivity (22). Furthermore, levels of glypican-1 were found to correlate with tumor burden and 
patient survival. 
 However, before we can rely on EVs for diagnosis, or take advantage of their dramatic 
influence of recipient cells, there must be rigorous assessment of EV cargo, and how the cargo 
correlates with disease progression. In the following chapters, I discuss several EV cargoes such 
as FAK, a MV cargo specific to oncogenic transformation, and survivin, a cargo specific to 
exosomes derived from chemotherapy treated cancer cells, and the contributions these EV 
cargoes make in influencing recipient cells.  
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CHAPTER 2 
1Microvesicle Cargo and Function Changes Upon the Induction of Cellular 
Transformation 
 
Extracellular vesicles (EVs), including exosomes and microvesicles (MVs), have emerged as 
a major form of intercellular communication, playing important roles in several 
physiological processes and diseases including cancer. EVs generated by cancer cells 
contain a variety of proteins and RNA species that can be transferred between cancer cells, 
as well as between cancer and non-transformed (normal) cells, thereby impacting a 
number of aspects of cancer progression. Here we show how oncogenic transformation 
influences the biogenesis and function of EVs using a mouse embryonic fibroblast (MEF) 
cell line that can be induced to express an oncogenic form of Dbl (for diffuse B cell 
lymphoma). While MEFs induced to express onco-Dbl generated a similar amount of MVs 
as the uninduced control cells, we found that MVs isolated from onco-Dbl-transformed 
cells contain a unique signaling protein, the ubiquitously expressed non-receptor tyrosine 
kinase, focal adhesion kinase (FAK). The addition of MVs isolated from MEFs expressing 
onco-Dbl to cultures of fibroblasts strongly promoted their survival and induced their 
ability to grow under anchorage-independent conditions, outcomes that could be reversed 
by knocking-down FAK and depleting it from the MVs, or by inhibiting its kinase activity 
using a specific inhibitor. We then showed the same to be true for MVs isolated from 
aggressive MDAMB231 breast cancer cells. Together, these findings demonstrate that the 
induction  of  oncogenic  transformation  gives  rise  to  MVs,  which  uniquely  contain  a  
1Currently in press as a manuscript by Bridget T. Kreger, Andrew L. Dougherty, Kai Su Greene, 
Richard A. Cerione, and Marc A. Antonyak in the Journal of Biological Chemistry. 
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signaling protein kinase that helps propagate the transformed phenotype, and thus may 
offer a specific diagnostic marker of malignant disease 
 
Introduction 
Classical intercellular signaling involves the secretion of growth factors, pro-inflammatory 
cytokines, and extracellular matrix proteins, by a cell into its local environment (1, 2). These 
soluble factors then bind to their corresponding receptors expressed in a neighboring cell and 
induce the activation of intracellular signaling events that determine whether a cell grows, 
differentiates, migrates, or dies (3). These types of paracrine signaling activities are required 
throughout development and for tissue homeostasis, while de-regulation of these events often 
leads to developmental abnormalities and the onset of diseases.  
The generation of EVs by cells has quickly become appreciated as another major form of 
intercellular communication with important consequences in biology (4-7). Cells generate two 
distinct types of EVs, MVs and exosomes. MVs typically range in size from 0.2-2.0µm in 
diameter, and are formed via the budding and release (shedding) of membrane-enclosed 
packages from plasma membranes. Exosomes represent the second major class of EVs. They are 
significantly smaller than MVs, averaging only 0.03-0.1µm in size, and are formed through a 
distinct mechanism. Specifically, exosomes are generated as a result of the endosomal sorting 
complex required for transport (ESCRT)- and Rab-dependent re-routing of multivesicular bodies 
(MVBs) containing endosomes from the lysosome, where they would be degraded, to the cell 
surface. The MVBs then fuse with the plasma membrane and release their contents (i.e. 
endosomes) into the extracellular environment, at which point they are referred to as exosomes. 
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One of the main reasons that MVs and exosomes have been attracting a good deal of 
attention has to do with the cargo they contain, which includes cell surface receptors, cytosolic 
signaling proteins, metabolic enzymes, and even nuclear proteins, as well as RNA transcripts and 
micro RNAs (1, 2, 6, 7). Once released from a cell, EVs can function in a paracrine or endocrine 
manner through the transfer of their cargo to a recipient cell (3, 4). This cargo is then used by the 
cell to elicit specific cellular processes or outcomes.  
Although it is beginning to be appreciated that both normal cell types and cancer cells 
generate MVs and exosomes, EVs have been most often studied in the context of cancer, where 
they have been shown to play important roles in the progression of the disease (4-9). For 
example, MVs generated by highly aggressive human cancer cells are capable of stimulating 
tumor angiogenesis, reorganizing the stroma to establish the tumor microenvironment, as well as 
promote tumor growth and chemoresistance (10-12). The role of MVs in cancer progression was 
exemplified in a study showing that a highly oncogenic form of the epidermal growth factor 
receptor (EGFR), known as the EGFR variant type III (EGFRvIII), is present in MVs generated 
by glioma cells engineered to express this truncated EGFR. When MVs from these glioma cells 
were isolated and then added to EGFRvIII-negative glioma cells, the EGFRvIII was transferred 
from the MVs to the cells where it triggered oncogenic signaling events that promoted cell 
growth and survival (8).  
Increasing evidence suggests that cancer cell-derived MVs also impact the behavior of 
normal cell types that can be found bordering a tumor (13, 14). For example, our laboratory has 
shown that MVs generated by the highly aggressive MDAMB231 breast cancer cell line are 
capable of conferring a transformed-like phenotype onto normal mammary epithelial cells and 
fibroblasts, including the ability to grow under serum-limiting, or anchorage-independent 
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conditions. We further showed that an important aspect of the mechanism underlying the ability 
of MVs to mediate such phenotypic changes involved the crosslinking of the extracellular matrix 
protein fibronectin, which is associated with MVs, through the acyl transferase activity of 
another MV-associated protein, tissue transglutaminase. This enabled the MVs to dock onto 
normal epithelial cells and fibroblasts through the binding of the MV-associated cross-linked 
fibronectin to integrins on the surfaces of theses cells (6). 
In addition to EVs acting locally to promote tumor growth, they can also impact cells at 
distant sites, through their ability to enter the bloodstream and circulate throughout the body. 
Thus, the isolation of EVs from blood samples is being actively pursued as a potential source of 
diagnostic information (15). Many lines of evidence have shown that high grade/highly 
aggressive cancer cells shed considerably more EVs than lower grade cancer cells and normal 
cells (16). In one such study, patients with malignant melanoma were found to have nearly twice 
the amount of EVs in their blood serum compared to normal patients (17). Moreover, a study 
conducted on glioblastoma patients found that the amount of EVs in the circulation increased 
proportionally to tumor volume (18). Collectively, these findings suggest that the levels of 
circulating EVs, and/or the cancer-specific cargo contained within these vesicles, could be used 
as potential diagnostic indicators.  
Given the importance of EVs in cancer progression, we set out to better understand the key 
differences between MVs generated by normal and transformed cells, as this information would 
shed additional light on how cancer cell-derived MVs impact recipient cells, as well as further 
examine their potential as diagnostic markers. Here, using an inducible model of cellular 
transformation, we show that the amount of MVs shed by non-transformed MEFs is comparable 
to that generated by MEFs transformed by inducing the expression of onco-Dbl (19), a truncated 
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nucleotide exchange factor (GEF) that constitutively activates members of the Rho family of 
small GTPases. However, we found that MVs from transformed MEFs were specifically 
enriched in the non-receptor tyrosine kinase FAK, despite this kinase being expressed at similar 
levels in both the non-transformed and transformed MEFs. We went on to determine that FAK is 
also preferentially expressed in MVs derived from several highly aggressive breast cancer cell 
lines. Moreover, we found that the presence of FAK in the MVs from the transformed MEFs, as 
well as the highly aggressive MDAMB231 breast cancer cells, has important functional 
consequences, namely, it enables MVs to promote cell survival and anchorage-independent 
growth. Overall, the findings reported here highlight that specific cargo is recruited to MVs upon 
oncogenic transformation, thus conferring these vesicles with unique functional capabilities.  
Results 
Onco-Dbl expression in MEFs induces cellular transformation 
The formation and shedding of MVs by cells is now appreciated as a form of intercellular 
communication with important roles in human cancer progression. These vesicles are also being 
aggressively pursued as a novel source of diagnostic information. However, there still remains a 
gap in our understanding of how cancer cell-derived MVs mediate their effects and how we 
might best utilize their unique properties for diagnostic purposes. Therefore, we took advantage 
of a well-defined, inducible system of oncogenic transformation to compare the cargo and 
functional properties of MVs isolated from transformed cells and their non-transformed 
counterparts. Specifically, this system involves MEFs that stably express a doxycycline-
regulated form of onco-Dbl, a truncated GEF that activates the small GTPases Rho and Cdc42 
(20-22).  
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When cultured in the presence of doxycycline, the expression of HA-tagged onco-Dbl in 
MEFs is inhibited (Figure 2.1A, top panel, first lane). However, 24 hours after placing the MEFs 
in medium lacking doxycycline, HA-tagged onco-Dbl is readily detected in lysates derived from 
these cells (compare the first and third lanes), with maximal expression occurring within 48 
hours (compare the third-fifth lanes). Thus, for all the experiments where MEFs expressing 
onco-Dbl are used, we first induced its expression for 48 hours prior to beginning the assays.  
As previously reported (19), marked actin cytoskeletal rearrangements accompanied the 
expression of onco-Dbl and its activation of the small GTPases Cdc42 and Rho. Figure 2.1B 
shows an example of an uninduced control MEF stained with an HA antibody and rhodamine-
conjugated phalloidin to label filamentous actin (F-actin). The uninduced control MEFs, which 
lacked onco-Dbl expression (top left panel), showed a typical fibroblast-like morphology (top 
right panel). However, upon the induction of HA-tagged onco-Dbl expression (Figure 2.1B, 
bottom left panel), there was a significant increase in the number and size of F-actin stress fibers 
(bottom right panel).  
We then subjected the uninduced control and onco-Dbl-expressing MEFs to soft agar and 
cell death assays. Soft agar assays determine the ability of cells to grow and form colonies under 
anchorage-independent conditions, an in vitro measure of tumorigenicity. Figure 2.1C shows that 
after 14 days in culture, the control MEFs remained as single cells (top panel). In contrast, the 
induction of HA-tagged onco-Dbl expression resulted in the formation of large colonies of cells 
(Figure 2.1C, bottom panel and Figure 2.1D). In order to examine how onco-Dbl expression 
influenced MEF viability, we then cultured uninduced control MEFs, as well as MEFs induced to 
express HA-tagged onco-Dbl, in medium lacking or containing serum for 48 hours. The cells 
were then collected, stained with DAPI to label their nuclei, and analyzed by fluorescent 
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Figure 2.1. The induction of onco-Dbl expression in MEFs leads to cellular 
transformation.  
(A) Western blot analysis using HA and actin antibodies was performed on lysates of MEFs 
stably expressing an inducible form of HA-tagged onco-Dbl after the removal of doxycycline 
(Dox) from the culturing medium for the indicated lengths of time. Molecular weight markers 
(in kDa) have been included along the right side of each blot. (B) Immunofluorescence using 
an HA antibody was performed on uninduced control MEFs and on MEFs induced to express 
onco-Dbl (onco-Dbl induced) for 48 hours (left panels). The cells were also stained with 
rhodamine-conjugated phalloidin to detect F-actin (right panels). (C) and (D) Soft agar assays 
were carried out on control MEFs (uninduced) and MEFs expressing onco-Dbl. 
Representative bright field images of the assays are shown in (C), while (D) shows the 
number of colonies that formed for each condition. (E) Cell death assays were performed on 
uninduced MEFs, and MEFs expressing onco-Dbl, by culturing them in serum-free medium 
supplemented without or with 2% serum, as indicated. Approximately 48 hours later, the cells 
were collected and stained with DAPI to identify condensed or blebbed (apoptotic) nuclei. 
The experiments in (A-E) were performed a minimum of 3 separate times, with each 
experiment yielding similar results. The data shown (in D and E) represents the mean ± 
standard deviation (SD). Student t-tests were performed. ***p<0.001. 
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microscopy for the appearance of condensed or blebbed nuclei, a hallmark of apoptosis. There 
was a nearly 18-fold increase in the number of control MEFs that died when cultured in serum 
free medium, compared to MEFs cultured in 2% serum (Figure 2.1E, compare the first two bars). 
However, onco-Dbl expression reduced the amount of cell death caused by serum-starvation to a 
similar extent as culturing the control MEFs in 2% serum (Figure 2.1E, compare the first and 
fourth bars).  
 
Comparison of MVs from control versus onco-Dbl-transformed MEFs 
We next used the inducible model of cellular transformation to determine how MVs 
generated by normal (non-transformed) cells differ from those generated by transformed cells. 
Given that various studies have suggested that high-grade and highly aggressive cancer cells 
generate more EVs compared to either lower grade cancer cells or their normal cellular 
counterparts (16, 18), we asked whether uninduced control MEFs generated less MVs than 
MEFs expressing onco-Dbl. Control MEFs and MEFs expressing HA-tagged onco-Dbl were 
treated with the fluorescent membrane dye FM1-43FX and visualized using fluorescent 
microscopy. Figure 2.2A shows that MVs could be detected along the surfaces of cells from both 
of these cultures. The MVs were then isolated from the conditioned media collected from an 
equivalent number of serum-starved control MEFs, or MEFs expressing onco-Dbl, using a 
method that involved a series of centrifugations to remove cells and cell debris, followed by a 
filtration step using a 0.22µm filter (Figure 2.2B). This approach allows for the separation of 
MVs from the population of smaller sized EVs known as exosomes. Transmission electron 
microscopy (TEM) performed on the MV preparations revealed that EVs averaging ~300-
400 nm in diameter could indeed be routinely isolated from each of these cell cultures (Figure 
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Figure 2.2. Control and onco-Dbl-transformed MEFs generate MVs.  
(A) Control MEFs (uninduced), and MEFs expressing onco-Dbl (onco-Dbl induced), were 
stained with the fluorescent membrane dye FM1-43FX to visualize MVs on their surfaces. 
Some of the MVs are indicated with arrows and the insets are magnifications of the boxed 
areas. Scale bar = 20µm. (B) Schematic of the MV isolation procedure used to prepare MVs 
lysates for Western blot analysis, or for use in biological assays. (C) TEM images of MVs 
isolated from the different MEF cultures. Scale bars = 500nm. (D) Western blot analysis using 
an anti-HA antibody to detect onco-Dbl expression, an IκBα antibody as a cytoplasmic 
marker, a flotillin-2 antibody as a MV marker, and an actin antibody as a loading control was 
performed on control MEFs (uninduced) and MEFs expressing onco-Dbl (lanes labeled whole 
cell lysates; WCL), as well as on the MVs that these cells generated (lanes labeled MVs). 
Molecular weight markers (in kDa) have been included along the right side of each blot. (E) 
NTA was performed on MVs isolated from an equivalent number of control MEFs and MEFs 
expressing onco-Dbl. The experiments (in A and C-E) were performed a minimum of 3 
separate times, with each experiment yielding similar results.  
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2.2C). A portion of these MV preparations were also lysed and analyzed by Western blot to 
detect the MV marker protein flotillin. Figure 2.2D shows that flotillin is readily detectable in the 
MVs isolated from both control MEFs and from cells expressing onco-Dbl (top panel, lanes 
labeled MVs). Importantly, the cytosolic signaling protein IkBa was only detected in the whole 
cell lysates (second panel, lanes labeled WCL), indicating that the MV preparations were devoid 
of cytosolic contaminants.  
These same MV preparations were also subjected to nanoparticle tracking analysis (NTA) 
to determine the size and amount of MVs in each sample. Consistent with our TEM results, NTA 
showed that the MVs generated by these cells range in size from ~200-700 nm, with most of 
them averaging ~300-400 nm (Figure 2.2E). Interestingly, this analysis also showed that the 
uninduced control MEFs actually shed slightly more MVs into their culturing medium than the 
MEFs expressing onco-Dbl (Figure 2.2E), indicating that non-transferred cells are capable of 
generating equivalent, if not slightly greater, amounts of MVs than their transformed 
counterparts.  
 
MVs generated by MEFs expressing onco-Dbl promote the survival and anchorage-independent 
growth of cells 
We then set out to determine whether MVs generated by non-transformed MEFs, versus 
MVs from MEFs transformed by onco-Dbl, exhibit distinct functional capabilities. Thus, MVs 
generated by each of these cell types were isolated, quantified using NTA, and normalized based 
on MV number. The MVs were then added to cultures of serum-starved NIH-3T3 cells for 48 
hours (Figure 2.3A), at which point the amount of cell death for each condition was determined 
by staining the cells with DAPI to identify condensed or blebbed (apoptotic) nuclei. 
76
Figure 2.3. Onco-Dbl-transformed MEFs generate MVs capable of strongly promoting 
cell survival and inducing cellular transformation.  
(A), Schematic of the cell death and soft agar assays performed. For the cell death assay, 
serum starved plates of NIH-3T3 cells were incubated without (serum starved) or with an 
equivalent amount of MVs derived from either control MEFs (Uninduced MVs) or MEFs 
induced to express onco-Dbl (Onco-Dbl Induced MVs). The MVs from the control MEFs 
were also added at twice the concentration (2x Unind. MVs). As a positive control, a plate of 
NIH-3T3 cells were maintained in medium supplemented with serum (2% serum). 
Approximately 48 hours later, the cells were analyzed for apoptotic nuclei. (B) The results of 
the cell death assay described in (A). Soft agar assays were carried out on NIH-3T3 
fibroblasts that were either left untreated (No MVs), or treated with MVs derived from 
control MEFs (Uninduced MVs) and MEFs expressing onco-Dbl (Onco-Dbl induced MVs). 
Representative bright field images of the soft agar assays are shown in (C), while (D) shows 
the number of colonies that formed for each condition. The experiments performed in (B-D) 
were performed a minimum of 3 separate times, with each experiment yielding similar 
results. The data shown in (B and D) represents the mean ± the SD. Student t-tests were 
performed. *p<0.05; ***p<0.001; n.s., not significant. 
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Approximately 60-70% of the NIH-3T3 cells cultured in serum-free medium underwent cell 
death (Figure 2.3B, first bar). When NIH-3T3 cells were cultured in serum-free media 
supplemented with MVs derived from uninduced control MEFs, a modest reduction (~30%) in 
cell death was observed (Figure 2.3B, compare the first and third bars). Doubling the amount of 
these MVs did not reduce the extent of cell death further (compare the third and fourth bars), 
suggesting a maximal MV dose for conferring a survival advantage had been achieved in these 
experiments. However, when NIH-3T3 cells were cultured in serum-free medium supplemented 
with MVs from MEFs expressing onco-Dbl, the apoptotic rate was dramatically reduced and 
approached the extent of protection from cell death that was provided when culturing cells in 2% 
serum (Figure 2.3B, compare the second and fifth bars).  
The ability of MVs derived from MEFs expressing onco-Dbl to induce the anchorage-
independent growth (i.e. colony formation in soft agar) of the non-transformed NIH-3T3 cell line 
was also determined (Figure 2.3A). As expected, NIH-3T3 cells either left untreated (no MVs), 
or treated with MVs from the uninduced control MEFs for 14 days, remained primarily as single 
cells (Figure 2.3C, first two panels). However, when the same cells were treated with MVs 
derived from the transformed MEFs they began to form colonies (Figure 2.3C, last panel, and 
Figure 2.3D, compare the first two bars and the third bar), similar to what was observed with 
MVs isolated from highly aggressive brain and breast cancer cells (6).  
These findings suggested that MVs generated by transformed cells may contain distinct 
cargo that enables them to promote the anchorage-independent growth and survival of cells to a 
much greater degree compared to MVs isolated from non-transformed MEFs. To identify such 
cargo, lysates prepared from control and transformed cells, as well as the lysates of the MVs 
shed by these cells, were subjected to Western blot analysis to detect proteins linked to cell 
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survival. We examined MV lysates for the presence of a number of signaling proteins linked to 
cell survival. One that stood-out was FAK, a non-receptor tyrosine kinase that is overexpressed 
and/or hyper-active in many different cancer cell types, where it has been shown to participate in 
the maintenance of the transformed phenotype, including the evasion of apoptosis and promotion 
of anchorage independent growth (23-27). In fact, targeting FAK for inactivation is currently 
being used as a strategy to treat several different types of human cancer (28, 29). Figure 2.4A 
shows that FAK is expressed at similar levels in control MEFs and MEFs expressing onco-Dbl 
(top panel; lanes labeled WCL). However, while FAK was only barely detectable in the MVs 
derived from control MEFs, a significantly greater amount of FAK was present in MVs derived 
from cells induced to express onco-Dbl (top panel, lanes labeled MVs). Quantifying the levels of 
FAK in MVs isolated from control MEFs, versus MVs obtained from MEFs expressing onco-
Dbl, indicated that there was ~12-fold more FAK in MVs generated by transformed cells (Figure 
2.4B).  
We then determined whether the non-receptor tyrosine kinase c-Src and the protein 
scaffold paxillin, two proteins that cooperate with FAK and mediate cell growth and survival 
(30, 31), are also enriched in MVs generated by the transformed MEFs. While similar amounts 
of c-Src were detected in MVs from the uninduced control MEFs and MEFs expressing onco-
Dbl (Figure 2.4A, second panel, lanes labeled MVs), paxillin was absent from both of these MV 
preparations (third panel, lanes labeled MVs). These findings further underscore that FAK is 
uniquely enriched in MVs generated by transformed MEFs. 
To determine if FAK was present in the smaller class of EVs referred to as exosomes, the 
total EVs shed by non-transformed and onco-Dbl-transformed MEFs were separated by 
collecting the MVs on a 0.22µm filter and comparing their protein contents to those of exosomes 
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Figure 2.4. MVs generated by transformed MEFs and aggressive breast cancer cells 
contain FAK.  
(A) Western blot analysis using FAK, Src, Paxillin, IκBα, and flotillin antibodies was 
performed on control MEFs and MEFs expressing onco-Dbl (lanes labeled WCL), as well as 
on the MVs that these cells generated (lanes labeled MVs). Note that FAK is uniquely 
enriched in MVs derived from the MEFs expressing onco-Dbl. (B) The relative amounts of 
FAK detected in MVs generated by control (uninduced) MEFs and MEFs expressing onco-
Dbl (onco-Dbl induced) was determined across several experiments. The data represents the 
mean ± SD. Student t-tests were performed. ***p<0.001. (C) Western Blot analysis using 
FAK, IκBα, and flotillin antibodies was performed on uninduced MEFs and MEFs expressing 
onco-Dbl (lanes labeled WCL), as well as on the exosomes (lanes labeled Exosomes) and 
MVs (lanes labeled MVs) these cells generated. The blots were also probed with a CD-63 
antibody, an exosome-specific marker. The vertical lines placed through the blots indicate 
where a small portion of each blot was deleted. Note that FAK is present only in the MVs 
from MEFs expressing onco-Dbl. (D) Western Blot analysis using FAK, IκBα, HA, and 
flotillin antibodies was performed on normal MCF-10A mammary epithelial cells and 
MDAMB231, BT-549, and Hs-578T breast cancer cells (lanes labeled WCL), as well as on 
the MVs that these various cell lines generated (lanes labeled MVs). The experiments in (A-
D) were performed a minimum of 3 separate times and molecular weight markers (in kDa) 
have been included along the right side of the blots shown in (A, C, and D).  
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collected from the flow-through following centrifugation at 100,000xg. Figure 2.4C shows that 
the exosome preparation contains the specific exosomal marker CD-63, whereas the MV fraction 
does not (second panel, compare the lanes labeled Exosomes and MVs). It should be noted that 
FAK is only present in whole cell lysates (WCLs), and lysates collected from MVs derived from 
transformed MEFs (top panel).  
We then examined whether the levels of FAK were similarly increased in MVs generated 
by human breast cancer cells. The non-malignant mammary epithelial MCF-10A cell line, 
together with several highly aggressive, triple-negative breast cancer cell lines including 
MDAMB231, BT-549, and Hs-578T cells, were cultured and the MVs shed by each of these cell 
lines were isolated. Figure 2.4D shows that each of these cell lines expressed comparable levels 
of FAK (top panel, lanes labeled WCL). However, while FAK was absent in MVs isolated from 
the normal mammary MCF-10A cell line, its expression was readily detectable in the MVs 
derived from each of the breast cancer cell lines (top panel, compare the lanes labeled MVs). 
 
FAK plays an important role in the ability of MVs from transformed cells to promote cell growth 
and survival 
 We set out to determine whether FAK in the MVs from the MEFs expressing onco-Dbl 
was necessary for their strong cell survival and anchorage-independent growth promoting 
capabilities. As a first step toward addressing this question, we collected MVs generated by 
control MEFs and MEFs expressing onco-Dbl, and confirmed that FAK is preferentially loaded 
in MVs isolated from cells expressing onco-Dbl (Figure 2.5A, second panel, compare lanes 
labeled MVs). Interestingly, we found that activated FAK, as well as the activated form of its 
major binding partner, c-Src (32), were both present in these MVs, as detected by Western 
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Figure 2.5. The FAK associated with MVs can be transferred to recipient cells and 
activate intracellular signaling events.  
(A) Lysates of control MEFs (uninduced) and MEFs induced to express onco-Dbl (lanes 
labeled WCL), as well as lysates of the MVs that these cells generated (lanes labeled MVs) 
were subjected to Western blot analysis using an antibody that recognizes FAK when it is 
phosphorylated on tyrosine 397 (P-FAKTyr397). The blot was also probed with FAK, P-c-
SrcTyr416, IκBα, and flotillin antibodies. (B) and (C) Multiple sets of MEFs expressing onco-
Dbl were either mock transfected, or transfected with an HA-tagged form of FAK (HA-FAK). 
(B) One set of the transfectants (lanes labeled WCL), and the MVs that they generated (lanes 
labeled MVs) were subjected to Western blot analysis using HA and flotillin antibodies. (C) 
the MVs generated by another set of transfectants was collected and then incubated with 
NIH-3T3 fibroblasts for 2 hours, at which point immunofluorescence using an HA antibody 
was carried out on the cells. The cells were also stained with phalloidin to label F-actin. Note 
that the HA-FAK can be detected as puncta on the surface of the cells treated with MVs 
expressing HA-FAK (arrows). (D) Serum starved cultures of NIH-3T3 fibroblasts were 
treated without (time=0) or with an equivalent amount of MVs isolated from either control 
MEFs (lanes labeled treatment with MVs from uninduced MEFs) or MEFs expressing onco-
Dbl (lanes labeled treatment with MVs from onco-Dbl induced MEFs) for the indicated 
length of time and lysed. Western blot analysis was performed on the cell lysates using P-
FAKTyr397, FAK, P-AKT, AKT, P-ERK 1/2, and ERK 1/2 antibodies. The experiments in (A-
D) were performed a minimum of 3 separate times, with each experiment yielding similar 
results. Molecular weight markers (in kDa) have been included along the right side of each of 
the blots shown in (A, B, and D).  
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blotting MV lysates with antibodies that detect FAK phosphorylated at tyrosine 397 (P-
FAKTyr397) and c-Src phosphorylated at tyrosine 416 (P-SrcTyr416) (Figure 2.5A, top two panels, 
fourth lane). These findings raise the interesting possibility that FAK and c-Src may form a 
complex in MVs that is capable of strongly activating downstream signaling events (33, 34).  
To demonstrate that the FAK present in the MVs can be transferred to recipient cells, we 
took advantage of the fact that transformed MEFs transiently transfected with a HA-tagged form 
of FAK (Figure 2.5B, top panel, lanes labeled WCL), generate MVs that contain the ectopically 
expressed protein (top panel, lanes labeled MVs). We then prepared MVs derived from onco-
Dbl-expressing MEFs that had been either mock transfected, or transfected with HA-tagged 
FAK, and incubated these preparations with cultures of NIH-3T3 fibroblasts for 2 hours, at 
which time the cells were washed extensively, fixed, and then stained with an HA-antibody and 
rhodamine-conjugated phalloidin to label F-actin. Figure 2.5C shows that the NIH-3T3 
fibroblasts treated with MVs from the mock-transfected cells lacked any detectable HA-FAK 
expression (upper left panel). On the other hand, HA-FAK could be detected as small puncta 
along the surfaces of cells treated with MVs collected from transformed MEFs ectopically 
expressing the FAK construct (lower left panel, see arrows). 
We then examined whether the activated FAK present in MVs can induce signaling events 
in recipient cells. MVs collected from either control MEFs or MEFs expressing onco-Dbl were 
added to cultures of serum-starved NIH-3T3 fibroblasts for increasing lengths of time. Figure 
2.5D shows that within 0.5 hours of treating cells with MVs from MEFs expressing onco-Dbl, an 
increase in the level of phosphorylated FAK could be detected, with maximal phosphorylation 
occurring at 1 hour (top panel, lanes labeled treatment with MVs from onco-Dbl induced MEFs). 
This increase in FAK phosphorylation was not observed in NIH-3T3 cells treated with MVs 
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isolated from control MEFs (top panel, lanes labeled treatment with MVs from uninduced 
MEFs). Because the MVs expressing HA-tagged FAK appear to remain primarily on the surface 
of recipient cells for up to 2 hours, we suspect that the FAK associated with MVs generated by 
transformed cells is most likely sending signals from the cell surface. Consistent with this idea, 
we have found that the phosphorylation level of AKT, a downstream effector of FAK (35), is 
preferentially activated in a time-dependent fashion by MVs from transformed cells (Figure 
2.5D, third panel). It is worth mentioning that this appears to be a specific signaling outcome, as 
the MVs isolated from both uninduced and onco-Dbl expressing MEFs were able to stimulate 
ERK activation to similar extents (Figure 2.5D, fifth panel).     
We then set out to build upon this finding by directly assaying whether the MV-mediated 
transfer of FAK to recipient cells accounted for the ability of MVs from MEFs expressing onco-
Dbl to strongly promote cell survival, by performing two sets of experiments. In the first set, we 
obtained conditioned medium from cultures of control MEFs, or MEFs expressing onco-Dbl, and 
treated them without or with the FAK III inhibitor, a small molecule that undergoes a covalent 
interaction with FAK and blocks its activation (36). MVs were then isolated from the 
conditioned medium using a 0.22µm filter to remove any unbound (freely soluble) inhibitor. A 
portion of the isolated MVs was lysed and Western blotted using phospho-FAKTyr397 and total 
FAK antibodies. While the MVs from the transformed MEFs treated with the FAK III inhibitor 
still contained FAK (Figure 2.6A, middle panel, compare the fifth and sixth lanes), the extent of 
its phosphorylation was greatly diminished (Figure 2.6A, top panel, compare the fifth and sixth 
lanes). These MVs were then added to cultures of NIH-3T3 cells that were being serum-starved. 
Two days later, the cells were collected and the amount of cell death for each condition was 
determined. Figure 2.6B shows that the relative ability of MVs from transformed cells to 
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Figure 2.6. The activated FAK associated with MVs from transformed MEFs is 
important for their cell growth and survival promoting capabilities.  
(A-C). MVs isolated from control MEFs (uninduced), or MEFs expressing onco-Dbl, were 
treated without or with 5µM of the FAK III inhibitor for 2 hours, at which point any unbound 
inhibitor was removed by filtration using a 0.22µm filter and extensive rinsing with PBS. (A) 
One set of the MV preparations (lanes labeled MVs), as well as the cells that generated the 
MVs (lanes labeled WCL), were lysed and subjected to Western blot analysis using P-
FAKTyr397, FAK, and flotillin antibodies. Molecular weight markers (in kDa) have been 
included along the right side of the blot. (B) Another set of the MV preparations was added to 
serum starved NIH-3T3 fibroblasts. Approximately 48 hours later the cells were collected and 
stained with DAPI to identify condensed/blebbed (apoptotic) nuclei. (C) Anchorage-
independent growth assays were performed on NIH-3T3 fibroblasts supplemented without 
(no MVs) or with another set of the MV preparations. The experiments in (A-C) were carried 
out a minimum of 4 separate times, each time yielding similar results. The data shown in (B 
and C) represents the mean ± SD. Student t-tests were performed. **p<0.01; ***p<0.001; 
n.s., not significant. 
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promote cell survival is completely lost under conditions where the activity of FAK associated 
with the MVs was inhibited, prior to adding the MVs to the serum-starved cells (compare the 
third and fourth bars). As a control, we verified that the relative extent of cell death for NIH-3T3 
cells incubated with MVs from control MEFs was unaffected by the FAK inhibitor (Figure 2.6B, 
compare first and second bars). Moreover, the ability of the MVs isolated from onco-Dbl 
expressing MEFs to induce the anchorage-independent growth of NIH-3T3 cells was also 
blocked by inhibiting the FAK activity associated with these MVs (using the FAK inhibitor) 
prior to adding them to the NIH-3T3 cells (Figure 2.6C, compare second and third bars). 
As a complimentary approach, we knocked down FAK in control and onco-Dbl expressing 
MEFs. The FAK-targeting siRNA reduced endogenous FAK expression by at least 85% in the 
control MEFs, and ~70% in the MEFs expressing onco-Dbl (Figure 2.7A, top panel, lanes 
labeled WCL). Knocking-down FAK in the transformed MEFs also effectively decreased FAK 
levels in their MVs (Figure 2.7A, top panel, lanes labeled MVs). Using NTA to determine the 
concentration of MVs in each of the various MV preparations, we normalized them and then 
compared the ability of an equivalent number of MVs isolated from control MEFs, or MEFs 
expressing onco-Dbl, that had been transfected with either control or FAK-targeting siRNAs, to 
promote cell survival. Figure 2.7B shows again that MVs from the MEFs expressing onco-Dbl 
are capable of promoting the survival of serum-starved NIH-3T3 cells (compare first and third 
bars). However, this advantage was lost when FAK levels in the MVs were reduced as a result of 
depleting FAK expression in the cells (Figure 2.7B, compare third and fourth bars).  
These experiments were expanded to determine whether FAK expressed in MVs derived 
from the highly aggressive MDBMB231 breast cancer cell line also promoted cell survival.  
Cultures of MDAMB231 cells were transfected with either control or FAK-targeting siRNA and 
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Figure 2.7. Knocking-down FAK expression in MEFs expressing onco-Dbl decreases the 
survival-promoting capabilities of their MVs.  
(A) Control MEFs, or MEFs induced to express onco-Dbl, were transfected with either 
control or FAK-targeting siRNA. Western blot analysis using a FAK antibody was performed 
on the cells (lanes labeled WCL) and the MVs that these cells generated (lanes labeled MVs). 
The blots were also probed with flotillin, actin, and IκBα antibodies. (B) NIH-3T3 cells were 
placed in serum free medium without or with an equivalent amount of MVs generated by 
each of the cells described in (A). About 48 hours later, the cells were stained with DAPI to 
identify the condensed/blebbed (apoptotic) nuclei. Note the amount of cell death seen for 
each condition is relative to the level of cell death observed in cells cultured with MVs from 
uninduced MEFs. (C) MDAMB231 breast cancer cells were transfected with either control or 
FAK-targeting siRNA. Western blot analysis using a FAK antibody was performed on the 
cells (lanes labeled WCL) and the MVs that these cells generated (lanes labeled MVs). (D) 
NIH-3T3 cells were cultured in serum free medium without or with an equivalent amount of 
MVs generated by the cells described in (C). About 48 hours later, the cells were stained with 
DAPI to identify condensed or blebbed (apoptotic) nuclei. The experiments in (A-D) were 
performed 3 separate times, each time yielding similar results. Molecular weight markers (in 
kDa) have been included along the right side of each blot shown in (A and C). The data 
shown in (B and D) represents the mean ± SD. Student t-tests were performed. *p<0.05; 
**p<0.01; ***p<0.001. 
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the levels of FAK in these cells, or in the MVs generated by the MDAMB231 cells, were 
determined. Figure 2.7C shows that the FAK-targeting siRNA decreased FAK expression in the 
cells, and also in the MVs from these cells, by ~75%. We then performed NTA on the MVs 
collected from MDAMB231 cells in order to normalize the MV preparations, so as to assess the 
function of an equivalent number of vesicles isolated from MDAMB231 cells that had been 
transfected with either control or FAK-targeting siRNAs. Figure 2.7D shows that the MVs 
isolated from MDAMB231 cells are able to confer a survival advantage upon serum-starved 
NIH-3T3 cells (compare first and third bars). However, this advantage is significantly reduced 
upon knocking-down FAK expression in the donor cells (Figure 2.7D, compare bars 3 and 4).  
 
Ectopically expressing a kinase-dead form of FAK in MVs derived from transformed MEFs 
reduces their cell survival promoting capabilities 
To further demonstrate the importance of FAK in the ability of MVs derived from 
transformed/cancer cells to promote cell survival, we ectopically expressed HA-tagged forms of 
wild-type FAK (FAK WT) and a kinase-dead form of FAK (FAK KD) that was generated by 
mutating an essential lysine residue (lysine 454) to arginine (37), in MEFs induced to express 
onco-Dbl. Figure 2.8A shows that both forms of FAK can be detected in the cells (panels labeled 
Donor MEFs), as well as in the MVs derived from the cells (panels labeled MVs from Donor 
MEFs). Thus, the kinase activity of FAK is not required for its incorporation into MVs. 
Interestingly, the ectopic expression of kinase-dead FAK in the MEFs expressing onco-Dbl led 
to a reduction in the overall levels of FAK activity in the MEFs (panels labeled Donor MEFS), as 
well as the MVs they generated (panels labeled MVs from Donor MEFs). The remaining portion 
of the isolated MVs were incubated with NIH-3T3 fibroblasts for 2 hours, and lysed. Western 
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blot analysis of these NIH-3T3 cell lysates revealed that the ectopically expressed HA-tagged 
forms of WT FAK and FAK KD could be detected in the cells (Figure 2.8A, panels labeled 
Recipient Fibroblasts).  
Survival assays were then carried out on serum-starved NIH-3T3 fibroblasts that were 
treated without (just serum-starved) or with MVs derived from onco-Dbl transformed MEFs, 
which had been mock transfected or transfected with either HA-FAK WT or HA-FAK KD. The 
ability of the ectopically expressed HA-FAK WT to become incorporated into MVs derived from 
the transformed MEFs did not change their ability to promote cell survival, compared to MVs 
from the mock transfected cells (Figure 2.8B, compare the second and third bars). On the other 
hand, MVs from the transformed MEFs containing the kinase-dead form of FAK significantly 
reduced their survival-promoting capabilities (compare the second and fourth bars). These 
findings, combined with those showing that transiently expressing HA-tagged FAK WT, but not 
FAK KD in NIH-3T3 fibroblasts (Figure 2.8C, top panel), is sufficient to promote cell survival 
(Figure 2.8D), supports the conclusion that activated FAK contained in the MV derived from 
transformed or cancer cells plays a key role in mediating their survival promoting capabilities.  
 
Discussion 
Only a short time ago, EVs were considered to be nothing more than cell debris. Now, 
however, EVs are recognized as a genuine form of cell-cell communication that has far reaching 
implications in physiological processes and disease progression (4, 38, 39). This has been 
perhaps best studied in the context of human cancer, where EVs have been linked to a number of 
stages of cancer progression including the shaping of the tumor microenvironment, angiogenesis, 
and the creation of the pre-metastatic niche at secondary sites of tumor colony formation (10, 40, 
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Figure 2.8. Ectopically expressing a kinase-dead form of FAK in MVs derived from 
transformed MEFs reduces their cell survival promoting capabilities.  
(A) MEFs induced to express onco-Dbl were mock transfected, or transfected with HA-
tagged forms of either FAK WT or FAK KD, and lysed. The MVs generated by these cells 
were also collected and a portion of them were directly lysed, while the rest of the isolated 
MVs were added to cultures of NIH-3T3 fibroblasts for 2 hours, before the cells were lysed. 
Western blot analysis using HA, P-FAKTyr397, FAK, and actin antibodies was performed on 
the transfected MEFs (panels labeled Donor MEFs), the MVs that the cells generated (panels 
labeled MVs from Donor MEFs), as well as on the NIH-3T3 cells that were treated without 
(no MVs added) or with the various MV preparations (panels labeled Recipient Fibroblasts). 
(B) NIH-3T3 cells were cultured in serum-free medium supplemented without (serum 
starved) or with MVs collected from onco-Dbl transformed MEFs that had been mock 
transfected, or transfected with HA-tagged forms of either FAK WT or FAK KD. 
Approximately 48 hours later, the cells were stained with DAPI to identify the condensed/
blebbed (apoptotic) nuclei. (C) Western blot analysis using HA, FAK, and actin antibodies 
was performed on NIH-3T3 cells that had been mock transfected, or transfected with either 
HA-tagged forms of FAK WT or FAK KD. (D) NIH-3T3 cells that had been mock 
transfected, or were ectopically expressing HA-tagged FAK WT or HA-tagged FAK KD, 
were serum starved for ~48 hours, at which point the cells were stained with an HA antibody 
to identify the transfectants and DAPI to identify condensed/blebbed (apoptotic) nuclei. The 
experiments in (A-D) were performed 3 separate times, each time yielding similar results. 
Molecular weight markers (in kDa) have been including along the right side of each blot 
shown in (A and C). The data shown in (B and D) represents the mean ± SD. Student t-tests 
were performed. *p<0.05; ***p<0.001; n.s., not significant.   
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41). The group of larger EVs, MVs, have been especially linked to changes in the tumor 
microenvironment, as demonstrated in studies showing that MVs isolated from the highly 
aggressive MDAMB231 breast cancer cell line and the U87 glioblastoma cell line, caused 
normal (non-transformed) cell lineages to acquire the ability to grow under serum-limiting 
condition, and survive apoptotic-inducing stresses (6).  
MVs have also caught the attention of clinical researchers and pharmaceutical companies, 
largely because of the realization that cancer cell derived EVs can be isolated from the blood 
samples of patients suffering from a number of types of cancer including brain, breast, prostate, 
kidney, and pancreatic (16, 42, 43). This has raised the exciting possibility that MVs, which, 
given their size, might be the more readily detectable EVs in plasma and tissue fluids, offer a 
novel and non-invasive source of diagnostic information. However, in order to realize such a 
possibility, it will be important to establish that MVs shed by transformed/cancer cells in fact 
contain unique cargo that is not present within their normal cellular counterparts.  
Here we set out to establish whether there might be differences both in the number of MVs 
generated by transformed/cancer cells, versus their non-transformed (non-cancerous) 
counterparts, as well as in the protein cargo that they contain. We started by using a well-defined 
system that allows for the inducible expression of the oncogenic Dbl protein in MEFs, resulting 
in the activation of Rho GTPases and giving rise to a number of transformed phenotypes. 
Somewhat surprisingly, in the light of the suggestions from some reports that the amount of EVs 
present in the bloodstream of a cancer patient can be correlated with the aggressiveness and/or 
grade of a particular tumor, we found that the amount of MVs generated by these cells did not 
increase upon the induction of oncogenic transformation. However, importantly, we did detect a 
specific change in the MV cargo from transformed cells. Specifically, we found that only MVs 
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generated by transformed cells contained the non-receptor tyrosine kinase FAK. Not only was 
FAK missing from MVs generated by non-transformed (normal) cells, it was also absent from 
exosomes isolated from either transformed or non-transformed MEFs. We then went on to 
demonstrate that the same is true in a number of human breast cancer cell lines, i.e. they shed 
MVs that specifically contained this important signaling kinase. 
The presence of FAK within MVs derived from transformed/cancer cells had important 
functional consequences. Indeed, we found that the ability of these MVs to specifically impart 
increased survival and anchorage-independent growth capabilities upon non-transformed cells 
was absolutely dependent upon the vesicles containing FAK. A particularly interesting aspect of 
these findings concerns how the MV-mediated transfer of FAK to recipient cells, that already 
contain endogenous levels of this protein kinase, is able to elicit a significant functional outcome. 
The answer may lie in our findings that the FAK in the MVs from transformed/cancer cells is 
already activated, and that these microvesicles also contain the major FAK signaling partner c-
Src. Thus, it is plausible that the MV-mediated transfer of just activated FAK, or an activated 
FAK-c-Src signaling complex, to recipient cells may provide a significant boost to the necessary 
signaling events within the cells to provide growth and survival benefits.  
It now appears clear that MVs derived from transformed or cancer cells can drive the 
recipient cells that they target to undergo marked phenotypic changes, as an outcome of the 
specific protein cargo that they contain and independent of any changes in total vesicle numbers. 
The finding that FAK is a unique cargo of these MVs is particularly significant due to the major 
role that this tyrosine kinase plays in cell migration, metastasis, and inhibition of apoptosis. In 
particular, FAK is able to activate downstream signaling pathways that ultimately prevent 
apoptosis by inhibiting the caspase-3 cascade (25).  Cancer cells take advantage of this 
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capability, often by over-expressing FAK (44), and therefore the ability of their MVs to transfer 
this important signaling kinase to surrounding recipient cells can obviously have important 
consequences for the microenvironment and tumorigenesis.   
Among the important questions for the future will be to better understand how MVs from 
transformed/cancer cells are loaded with their unique cargo, i.e. what are the mechanisms by 
which certain key proteins are recruited to the maturing MV while others are excluded. 
Although, there is a good deal that we still need to learn, it is becoming increasingly clear that 
the generation of MVs with specific cargo will not only have important implications for cancer 
progression, but also in the development of new therapeutic strategies to block the spread of 
disease. Moreover, by taking advantage of the presence of specific cargo such as FAK in cancer 
cell-derived MVs, new opportunities will emerge for the development of diagnostic disease 
markers.  
 
Materials and Methods 
Cell culture and transfections 
The tetracycline-off inducible onco-Dbl MEF cell line was generated as described previously 
(19). The cells were maintained in DMEM supplemented with 10% Tet system-approved fetal 
bovine serum (FBS) (Clontech), 100 μg/mL G418 (Gibco), and 1 μg/mL doxycycline (Sigma). 
To induce onco-Dbl expression, the cells were trypsinized and then plated in doxycycline-free 
culturing medium, where any residual doxycycline remaining in the cultures was removed by 
replacing the medium 6 hours after plating the cells. NIH-3T3 cells were maintained in DMEM 
supplemented with 10% calf serum (Clontech), while the normal mammary MCF10A epithelial 
cell line, as well as the MDAMB231, BT-549, and Hs-578T breast cancer cell lines, were grown 
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in RPMI 1640 supplemented with 10% FBS. Expression constructs encoding HA-tagged forms 
of either wild-type FAK (HA-FAK WT), or a kinase dead form of FAK (HA-FAK KD) that was 
generated by mutating lysine 454 to arginine (37), were transfected into cells using 
Lipofectamine (Invitrogen). Control and FAK-targeting siRNAs (Cell Signaling) were 
introduced into cells with Lipofectamine 2000 (Invitrogen).  
 
Fluorescent Microscopy 
Cells grown on glass coverslips were either transfected without or with the indicated expression 
constructs and siRNAs, or were treated with MVs isolated from MEFs expressing onco-Dbl and 
HA-tagged FAK WT, and then cultured as indicated. The cells were fixed with 3.7% 
formaldehyde, permeabilized with phosphate buffered saline (PBS) containing 0.1% Triton-
X100, and blocked with 10% bovine serum albumin diluted in PBS. The cells were stained with 
a HA rabbit polyclonal antibody (Covance) at a dilution of 1:500, followed by incubation with an 
Oregon green 488-conjugated secondary antibody (Molecular Probes). Rhodamine-conjugated 
phalloidin (Life Technologies) and 4’,6-diamidino-2- phenylindole (DAPI) (Sigma) were used to 
label actin filaments and nuclei, respectively. To detect MVs on the surfaces of cells, cultures of 
cells were incubated with the fluorescent membrane dye FM1-43FX (Invitrogen) diluted to 
5 µg/ml in PBS for 1 minute, and fixed on ice for 20 minutes. All cells were visualized using a 
Zeiss Axioscope with a 63X oil objective lens. Digital images of the cells were taken using a 
Sensicam qe camera (Cooke Company) and processed using IPLABS software (BD 
Biosciences). 
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Isolation of MVs and exosomes 
For the experiments involving MVs, the conditioned media collected from 2.0x106 serum starved 
cells was subjected to two consecutive centrifugations at 300×g to clarify the media of cells and 
cell debris. The partially clarified media was filtered using a Steriflip PVDF filter with a 0.22µm 
pore size (Millipore) and rinsed 3 times with PBS to remove soluble factors. For cell-based 
assays, the MVs retained by the filter (vesicles larger than 0.22µm in diameter) were 
resuspended in serum-free medium. To generate MV lysates, the MVs retained by the filter were 
lysed using 200 ml of lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 
1 mM DTT, 1 mM NaVO4, 1 mM b-glycerol phosphate, and 1 μg/mL each of aprotinin and 
leupeptin). Whole cell lysates (WCLs) were prepared by rinsing dishes of cells with PBS, adding 
1 mL of lysis buffer, and scraping the cells off the plate. Exosomes were isolated from the 
conditioned medium that flowed-through the 0.22µm Steriflip filter (i.e. vesicles smaller than 
220nm) by centrifugation at 100,000xg for 2 hours. The pelleted exosomes were then lysed with 
200µl lysis buffer. The resulting MV, exosome, and cell lysates were centrifuged at 13,000 rpm 
for 10 minutes and the supernatants were then analyzed.  
 
Immunoblot Analysis 
The protein concentrations of the cell lysates, as well as the MV and exosome lysates, were 
determined using the Bio-Rad DC protein assay (Bio-Rad). The lysates were normalized by 
protein concentration, resolved by SDS-PAGE, and then the proteins were transferred to PVDF 
membranes. The membranes were incubated with various primary antibodies including beta-
actin (Sigma, 5316), FAK (Cell Signaling, 3285S), flotillin-2 (Cell Signaling, 3436S), phospho-
FAKTyr397 (Cell Signaling, 3283S), phospho-src (Cell Signaling, 2101S), Src (Cell Signaling, 
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2123P), paxillin (BD, 612405), HA (Biolegend, 901503), IκBα (Cell Signaling, 9242), CD63 
(ThermoFisher, 10628D), phospho-ERK (Cell Signaling, 9106), ERK (Cell Signaling, 9102), 
phospho-AKT (Cell Signaling, 2965S), AKT (Cell Signaling, 9272S), diluted 1:1000 in 20 mM 
Tris, 135 mM NaCl, and 0.02% Tween 20 (TBST). The primary antibodies were detected with 
HRP-conjugated secondary antibodies (Cell Signaling) followed by exposure to ECL reagent 
(Pierce). 
 
Anchorage-independent Growth Assay 
Control MEFs, MEFs expressing onco-Dbl, or Parental NIH-3T3 cells were plated at a density of 
8 × 103 cells/mL in growth medium containing 0.3% agarose, with or without MVs as indicated, 
onto a base layer composed of growth medium containing 0.6% agarose in 6-well dishes. The 
soft-agar cultures were re-fed every third day, including the addition of freshly prepared MVs 
where indicated. After 14 days, the number of colonies that formed for each condition was 
counted. Each of the assays was preformed a minimum of three times and the results were 
averaged.  
 
Cell Death Assays 
Parental NIH-3T3 cells, or NIH-3T3 cells transfected with the indicated constructs, were plated 
in each well of a 6-well dish and then cultured in medium containing 2% calf serum or serum-
free medium supplemented without or with 1×107 MVs derived from control MEFs, MEFs 
expressing onco-Dbl, or MDAMB231 cells. Twenty-four hours later, the cells were treated with 
an additional dose of freshly prepared MVs. Forty-eight hours from the start of the assay, the 
cells were stained with DAPI for viewing by fluorescent microscopy. Cells undergoing apoptosis 
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were identified by nuclear condensation or blebbing and the percentage of cell death was 
determined by calculating the ratio of apoptotic cells to total cells for each condition examined.   
 
Nanoparticle Tracking Analysis (NTA) 
The sizes and concentrations of EVs in a given sample were determined using a NanoSight 
NS300 (Malvern). The samples were diluted in PBS made from ultra-pure water and passed 
through the beam path to detect EVs as points of diffracted light moving rapidly under Brownian 
motion. Five 60-second digital videos of each sample were taken, analyzed to determine the 
concentration and size of the individual EVs based on their movement, and then results were 
averaged together. 
 
Transmission Electron Microscopy (TEM) 
Five μl of a MV preparation resuspended in PBS were added to a carbon-coated, 300-mesh 
copper grid and then stained with 1.75% uranyl acetate. Once dry, the samples were imaged 
using the FEI T12 Spirit 120 kV field emission TEM at Cornell’s Center for Materials Research 
(CCMR), supported by NSF MRSEC award number: NSF DMR-1120296. 
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CHAPTER 3 
Survivin is enriched in cancer cell-derived exosomes upon treatment with Paclitaxel 

The generation of extracellular vesicles (EVs), including exosomes and microvesicles 
(MVs), by cancer cells plays important roles in promoting several aspects of cancer 
progression, including chemoresistance. EVs mediate their effects by transferring their 
cargo to target cells, which includes a specific set of signaling proteins, RNA transcripts, 
and cytoskeletal components. However, how cargo is selectively trafficked to EVs is 
unclear. We have discovered that treating MDAMB231 breast cancer cells with the 
chemotherapy paclitaxel, which functions by stabilizing microtubules, significantly 
increases the amount of survivin in the EVs shed by these cells. We then go on to show 
that survivin is specifically enriched in the class of EVs known as exosomes. Exosomes 
collected from MDAMB-231 cancer cells treated with paclitaxel promoted the survival of 
recipient fibroblasts and other breast cancer cells (e.g. SKBR3 cells) exposed to serum-
starvation and paclitaxel treatment, an effect that was lost when survivin was depleted 
from these exosomes by siRNA. Overall, these results highlight how a specific protein (e.g. 
survivin) is selectively packaged into exosomes, as well as shed light on a potential 
mechanism underlying paclitaxel resistance.  
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Introduction 
Breast cancer remains one of the most prevalent forms of cancer, with 1 in 8 women 
being diagnosed with invasive breast cancer in their lifetime (1). Treatment regiments for these 
patients typically include irradiation, surgery, and chemotherapy treatment. However, as is the 
case with many cancer therapies, resistance and tumor recurrence are common and often result in 
patient death. Thus there is an overriding need to better understand the mechanisms underlying 
therapy resistance.  
There are several mechanisms through which cancer cells can overcome the cytotoxic 
effects of chemotherapeutic agents. One such mechanism that is attracting a good deal of 
attention involves the generation of EVs by cancer cells (2, 3). EVs have the ability to act in both 
endocrine and paracrine fashions through the transfer of cargo to a recipient cell (4, 5). The cargo 
contained within EVs includes a variety of cell surface receptors, cytosolic signal proteins, 
metabolic enzymes, cytoskeletal proteins, and even nuclear proteins (6-8). Moreover, they also 
contain RNA transcripts and micro RNAs that are known to influence growth and survival 
responses (9-11). EVs derived from highly aggressive cancer cells have been shown to promote 
cell migration, tumor angiogenesis, tumor growth, and cell survival, making them an attractive 
target for therapy (12-14).  
Exosomes are considered one of the major classes of EVs and they range in size from 30-
100nm (15, 16). Exosomes are formed by a re-routing of the multivesicular bodies (MVBs) in 
the endosomal pathway from the lysosome (where they would typically be degraded) to the cell 
surface (17). The MVB then fuses with the plasma membrane and releases its contents (termed 
exosomes) into the extracellular space. Microvesicles (MVs) represent a distinct class of EVs 
that have the propensity to be much larger than exosomes, ranging in size between 200nm-2µm 
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(15). MVs also differ from exosomes on how they are generated, as they bud and are released 
(shed) directly from the plasma membrane (13).  
Although there are several potential treatment options for breast cancer patients, taxanes 
have emerged as a frontline treatment against malignancies of not only the breast, but also the 
lung and ovaries (18). Taxanes, including paclitaxel (also known as taxol), function by disrupting 
the normal dynamic properties of microtubules (19). Microtubules normally go through cycles of 
polymerization and disassembly, which is especially important for cell division. Paclitaxel 
functions by binding to the beta subunit of microtubules and prevents the formation of a proper 
mitotic apparatus. Thus, paclitaxel blocks cells from progressing through the G2/M phase of cell 
cycle, leading to cell cycle arrest and eventually cell death (20).   
Survivin is a protein characterized by its ability to prevent cell death, with its expression 
is normally being restricted to early embryo development and is absent in terminally 
differentiated cells (21). However, it is frequently expressed in cancer cells (22). Survivin 
expression is associated with poor patient prognosis, chemotherapy resistance, and increased 
tumor recurrence (23-26). This has caused survivin to be proposed as a marker of oncogenic 
transformation, and it is also being targeted as a potential therapy to treat cancer (27).  
Survivin regulates cell cycle progression by interacting with aurora B kinase as a member 
of the chromosomal passenger complex responsible for the cell cycle checkpoint of faithful 
separation of sister chromatids into daughter cells (28). It has been shown that its interaction with 
microtubules in cell cycle progression is sufficient to control microtubule stability and facilitate 
checkpoint evasion, and to promote resistance to paclitaxel chemotherapy by preserving the 
integrity of the mitotic apparatus (29, 30). Survivin overexpression in cancer has been shown to 
overcome the apoptotic checkpoint at G2/M and favor abnormal progression of transformed cells 
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through mitosis even after paclitaxel treatment. Survivin is also a member of the “inhibitor of 
apoptosis” family and blocks cell death by inhibiting the activation of caspases. There are several 
mechanisms proposed by which survivin protects cells from apoptosis. The most studied model 
is based on survivin’s ability to bind to the proapoptosis protein Smac/Diablo, sequestering it 
from blocking the activity of X-linked inhibitor of apoptosis protein (XIAP). XIAP is then free to 
directly bind caspase-3, caspase-7, and caspase-9, thereby preventing cell death (31, 32). The 
less frequently supported mechanism involves the direct binding of survivin to caspase-3 and 
caspase-7 (33).  
In this study, we propose a novel mechanism by which breast cancer cells might become 
resistant to paclitaxel. Specifically, we found that treating MDAMB-231 breast cancer cells with 
paclitaxel causes them to generate exosomes that are enriched with survivin, a protein known to 
promote cell survival and drug resistance (34). These exosomes are able to transfer survivin to 
fibroblasts, as well as to other cancer cells, and promote their survival under conditions of serum 
deprivation and after treatment. 
 
 
Results 
Cancer cells shed exosomes that promote survival 
 EVs, including exosomes and MVs, have emerged as a major form of intercellular 
communication that play significant roles in cancer progression, including promoting drug 
resistance (2, 35, 36). The specific cargo contained within these EVs is vital for their biological 
function. However, whether chemotherapy treatments alter the cargo and function of exosomes 
generated by cancer cells is not clear.  
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 To investigate this question, we first determined the amounts and sizes of exosomes that 
were generated by the triple negative breast cancer cell line, MDAMB-231. The conditioned 
medium from cultures of serum-starved MDAMB-231 cells was collected and the exosomes in 
the medium isolated using an approach developed in the laboratory that involves various 
centrifugation and filtration steps (Figure 3.1A). This approach effectively separates the 
exosomes from cells and cell debris, as well as from the larger class of EVs referred to as MVs. 
Lysates were subjected to Western blot analysis and the exosomal marker CD-63 was detected in 
the exosomal fraction (Exos), the total EVs (EVs), and the cells (WCL), but was not detected in 
the MVs (MVs) (Figure 3.1B, top panel). Importantly, the cytosolic signaling protein IκBα was 
only detected in the whole cell lysates (third panel, lanes labeled WCL), indicating that the MV 
preparations were devoid of cytosolic contaminants. The exosome preparations were then 
analyzed by electron microscopy (Figure 3.1C) to determine the sizes of the vesicles. Figure 
3.1D is a histogram generated by analysis of TEM images and shows that most of the EVs 
detected were between ~30-40nm in diameter, consistent with the known size of exosomes.  
We then determined whether the exosomes derived from the MDAMB-231 cells were 
capable of promoting cell survival. The removal of serum from NIH-3T3 fibroblasts in culture 
for extended periods of time strongly induces cell death, compared to cells maintained in 
medium containing 2% serum, (Figure 3.1E, compare bars 1 and 2). However, when fibroblasts 
were cultured in serum-free medium supplemented with exosomes from MDAMB-231 cells, 
there was an approximately 30% decrease in the number of cells that died after 48 hours (Figure 
3.1E, compare bars 1 and 3).  
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Figure 3.1. MDAMB-231 breast cancer cells shed exosomes that can promote survival. 
(A) Outline of procedure used for collecting exosomes for Western blot analysis, or use in 
biological assays. (B) Western blot analysis using CD-63, IκBα, and actin was performed on 
MDAMB-231 cells (lane labeled WCL), as well as on the exosomes (lane labeled Exos) and 
MVs (lane labeled MVs), and the total EVs (lane labeled EVs) these cells generated. (C) 
TEM images of exosomes isolated from MDAMB-231 cells. Scale bars = 50nm. (D) 
Histogram of the diameter of exosomes collected from MDAMB-231 cells determined by 
analysis of TEM images. (E) Cell death assays were performed on NIH-3T3 fibroblasts 
cultured in serum-free media, media containing 2% serum, or serum-free media containing 
exosomes derived from MDAMB-231 cells to assess the survival-promoting capabilities of 
the exosomes. The experiments were performed a minimum of 3 separate times. The data 
shown represents the mean ± SD.  
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Exosomes derived from Paclitaxel-treated MDAMB-231 cells promote cell survival better than 
those from control cells.  
 Since the chemotherapy paclitaxel is commonly used as a frontline treatment for breast 
cancer patients, we were interested in determining whether the exosomes generated by 
MDAMB-231 cells would change after being treated with this drug. We first demonstrated the 
effectiveness of paclitaxel by performing immunofluorescence on MDAMB-231 cells treated 
without or with 50nM paclitaxel using a tubulin antibody. Figure 3.2A shows that microtubules 
can be detected throughout the DMSO treated control cell (top panel). However, paclitaxel 
treatment caused a large increase in the number of microtubules present in the MDAMB-231 
cells (bottom panel), consistent with the idea that paclitaxel stabilizes microtubules (18, 37). A 
proliferation assay was then performed on MDAMB-231 cells treated with either DMSO or a 
low dose of paclitaxel (50nM). Figure 3.2B shows that paclitaxel treatment completely inhibited 
the growth of the cancer cells. 
Next, we determined how the amount of exosomes generated by MDAMB-231 cells was 
impacted by paclitaxel treatment. The exosomes generated by an equivalent number of 
MDAMB-231 cells, treated with either DMSO or paclitaxel, were collected and then subjected to 
nanoparticle tracking analysis (NTA) to determine exosome amounts. Interestingly, there was 
consistently an approximately 1.5 fold greater amount of exosomes produced by the paclitaxel 
treated cells, compared to those treated with the vehicle alone (Figure 3.2C). However, electron 
microscopy performed on the exosomes generated by the paclitaxel treated MDAMB-231 cells 
revealed that these vesicles were comparable in size to those generated by control MDAMB-231 
cells (compare Figure 3.2D and 3.2E to Figures 3.1C and 3.1D).  
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Figure 3.2. Exosomes derived from paclitaxel-treated MDAMB-231 cells promote 
survival beyond exosomes derived from control-treated cells.  
(A) Immunofluorescence using an anti-tubulin antibody was performed on MDAMB-231 
breast cancer cells treated with either DMSO vehicle control, or 50nM paclitaxel. (B) To 
demonstrate the effect of the paclitaxel treatment on cell growth, a proliferation assay was 
performed on MDAMB-231 cells treated with either DMSO vehicle control, or 50nM 
paclitaxel. (C) The relative amounts of exosomes generated by control (DMSO) 
MDAMB-231 cells, and cells treated with 50nm paclitaxel (PTX) were determined across 
several experiments. (D) TEM images of exosomes isolated from MDAMB-231 cells treated 
with 50nM paclitaxel. (E) Histogram of the diameter of exosomes collected from 
MDAMB-231 cells determined by analysis of TEM images. (F) Cell death assays performed 
on NIH-3T3 fibroblasts, comparing the survival-promoting effects of quantified exosomes 
derived from DMSO or paclitaxel treated MDAMB-231 cells. As a control, cells were also 
plated in serum-free media, or in the presence of 2% serum. Relative cell death was 
determined after 48 hours. The experiments were performed a minimum of 3 separate times. 
The data shown represents the mean ± SD.  
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The ability of the exosomes derived from the paclitaxel-treated MDAMB-231 cells to 
promote cell survival was then assayed. The exosomes generated by MDAMB-231 cells treated 
with either DMSO, or 50nM paclitaxel, were collected. Based on our NTA results (see Figure 
3.2C), the exosome amounts were normalized and then added to serum-starved cultures of NIH-
3T3 cells. A day later, the medium and exosomes on the cells were replenished, and one day 
after that (48 hours after the start of the assay), the cells were collected and analyzed for 
apoptosis, as read out by the appearance of nuclear condensation and blebbing. Figure 3.2F 
shows fibroblasts that had just been serum-starved (bar labeled No Exos) underwent a high level 
of cell death, compared to cells maintained in medium containing serum (bar labeled 2% Serum), 
i.e. the positive control. Fibroblasts incubated with exosomes derived from DMSO treated 
MDAMB-231 cells were again able to reduce the amount of cell death caused by serum 
starvation, by about 30% (compare bars 1 and 3). Importantly, increasing the amount of 
exosomes used from these cells did not further reduce the number of cells that died (compare 
bars 3-5), suggesting that a maximal effect was attained with 0.5 million exosomes/culture. 
However, when the same experiment was performed with exosomes derived from paclitaxel-
treated cells, an even greater survival advantage was observed. Indeed, an ~80% reduction in the 
amount of serum starvation-induced cell death was attained with these exosomes (Figure 3.2F, 
compare bars 6 and 7). 
These findings suggest that there is most likely something unique about the cargo in the 
exosomes from paclitaxel-treated MDAMB-231 cancer cells that enables them to strongly 
protect cells from serum starvation-induced cell death.  
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Paclitaxel-treated cells generate exosomes that are enriched with survivin. 
 In order to determine what cargo in exosomes derived from paclitaxel-treated MDAMB-
231 cells is responsible for their cell survival promoting capability, lysates of DMSO- or 
paclitaxel-treated MDAMB-231 cells, as well as from the exosomes and MVs that these cells 
released, were generated. The lysates were subjected to Western blot analysis using a number of 
different antibodies against several proteins involved in cell survival. The protein whose 
expression consistently changed the most in exosomes from the paclitaxel-treated cells was the 
inhibitor of apoptosis protein, survivin. Figure 3.3A shows that survivin was detected at 
relatively low levels in exosomes from DMSO treated control cells (top panel, lanes labeled 
DMSO). However, it was highly enriched in exosomes from the paclitaxel-treated MDAMB-231 
cells (top panel, lanes labeled PTX). On average, ~30-fold more survivin was detected in 
exosomes derived from paclitaxel-treated MDAMB-231 cells compared to exosomes from 
control-treated cells (Figure 3.3B). Moreover, we found that the enrichment of survivin in 
exosomes is specific for this class of EVs, as the larger class of EVs, MVs, isolated from the 
paclitaxel-treated MDAMB-231 cells lacked survivin expression (Figure 3.3A, top panel, lanes 
labeled PTX). Interestingly, the levels of survivin in the cells did not change significantly in this 
experiment (Figure 3.3A, lanes labeled WCL), or in an experiment where MDAMB-231 cells 
were treated with paclitaxel for increasing lengths of time (Figure 3.3C, top panel). This suggests 
that the increased levels of survivin in exosomes from paclitaxel-treated MDAMB-231 cells 
cannot be explained by an upregulation of the protein in the cells.  
 The subcellular localization of survivin in MDAMB-231 cells was then determined by 
immunofluorescence. The survivin in DMSO-treated cells was predominantly nuclear, as 
expected (38). However, after exposing the cells to paclitaxel for 12 hours, more survivin could 
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Figure 3.3. Paclitaxel treatment leads to the enrichment of survivin in exosomes.  
(A) Western blot analysis using survivin, flotillin, IκBα, and CD-63 antibodies was performed 
on lysates prepared from exosomes (Exos), microvesicles (MVs), and cell (WCL) fractions 
after cells were treated with either DMSO or 50nM paclitaxel. Note the increase in survivin 
signal detected in exosomes derived from paclitaxel treated cells. (B) The relative amounts of 
survivin detected in Exos generated by control (DMSO) MDAMB-231 cells, and cells treated 
with 50nm paclitaxel (PTX), were determined across several experiments. (C) Whole cell 
lysates prepared from paclitaxel-treated MDAMB-231 cells do not show an increase in 
survivin expression comparable to the enrichment seen in the exosome fraction. (D) 
Immunofluorescence using an anti-survivin antibody and DAPI (to indicate nuclear 
localization) was performed on MDAMB-231 cells treated with either DMSO or 50nM 
paclitaxel. Arrows indicate punctate detection of survivin after paclitaxel treatment. (E) 
Western blot analysis was performed using a survivin antibody on lysates collected from 
NIH-3T3 fibroblasts, MDAMB-231 cells, U87 glioblastoma cells, SKBR3 cells, and the 
exosomes generated after cells were treated with DMSO or 50nm paclitaxel. (F) Western blot 
analysis was performed on lysates collected from exosomes derived from MDAMB-231 cells 
that had been subjected to a panel of chemotherapy agents. Note the increase in survivin 
localization to the exosomes only after treatment with the microtubule disruptor nocodazole 
(NDZ) and microtubule stabilizer paclitaxel (PTX). The experiments were performed a 
minimum of 3 separate times. 
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be detected in the cytosol, appearing as small puncta (Figure 3.3D, see arrows). We then 
examined whether treating various cell lines with paclitaxel could alter the levels of survivin 
present in their exosomes. Exosomes were collected from DMSO or paclitaxel-treated NIH-3T3 
cells, which does not express survivin, as well as from aggressive breast cancer cell line 
MDAMB-231, the glioblastoma cell line U87, and the less aggressive breast cancer cell line 
SKBR3 (Figure 3.3E). Survivin levels increased in exosomes derived from paclitaxel-treated 
cancer cells. 
Due to other studies demonstrating that survivin activity and cellular localization can 
change in response to a variety of cell stresses and stimuli, we next investigated whether survivin 
was similarly enriched in exosomes derived from MDAMB-231 cells treated with various 
chemotherapeutic agents, or when treated with inhibitors known to block the activation of 
proteins important for driving the transformed state. The drugs and inhibitors used included 
microtubule disruptors (nocodazole and paclitaxel), a MEK inhibitor (PD98059), metabolic 
inhibitors (BPTES and 968), DNA synthesis inhibitors (doxorubicin, 5-FU, etoposide, and 
cisplatin), inhibitors of growth factor receptors (Gefitinib and AG538), a blocker of actin 
polymerization (Cytochalasin D), and the HSP90 inhibitor 17-AAG. The exosomes generated by 
the MDAMB-231 cells treated with each of the drugs/inhibitors were collected and then 
subjected to Western blot analysis using survivin and flotillin antibodies. Figure 3.3F shows that 
a roughly equivalent amount of flotillin (an exosome marker) was detected in each of these 
samples, suggesting that the cells were still capable of generating exosomes in response to each 
of the treatments (Figure 3.3F, bottom panel). However, when the same exosome lysates were 
probed for survivin, differences were observed. Only the microtubule disruptor nocodazole 
caused a similar enrichment of survivin in exosomes as paclitaxel (Figure 3.3F, top panel). This 
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indicates that the enrichment of survivin in exosomes derived from cells exposed to various 
stresses is not a common response, but rather appears to occur specifically when microtubule 
dynamics in cells are disrupted. 
 
Survivin is necessary for exosome-dependent survival.  
 We set out to determine if survivin in exosomes derived from MDAMB-231 cells treated 
with paclitaxel was necessary for their strong cell survival promoting capabilities. To this end, 
we either mock transfected MDAMB-231 cells, or transfected them with a survivin-specific 
siRNA, and then treated the cells with either DMSO or paclitaxel as outlined in Figure 3.4A. The 
siRNA reduced survivin expression levels in the cells by at least 90% (Figure 3.4B, blots labeled 
WCL) and, correspondingly, in the exosomes from the paclitaxel-treated MDAMB-231 cells 
(Figure 3.4B, blots labeled exosomes). The capability of the exosomes from the paclitaxel-
treated cells depleted of survivin to promote cell survival was then assessed. Figure 3.4C shows 
again that exosomes collected from paclitaxel-treated cells (PTX Exos) are better than those 
from control cells (DMSO Exos) at promoting the survival of serum-starved NIH-3T3 fibroblasts 
(compare bars 1 and 2). However, this advantage was completely lost when survivin was 
knocked down in the exosomes (Figure 3.4C, compare bars 2 and 4). These experiments were 
also carried out using a less aggressive SKBR3 breast cancer cell line as the recipient cell. Figure 
3.4D again shows that exosomes derived from MDAMB-231 cells treated with paclitaxel were 
able to promote the survival of serum-starved SKBR3 cells, while this effect was again lost when 
survivin was depleted from the exosomes using siRNA.  
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Figure 3.4. Knocking down survivin in MDAMB-231 cells decreases their survival-
promoting capabilities.  
(A) Schematic of the cell death assays performed. Serum-starved plates of recipient cells 
were incubated with exosomes derived from MDAMB-231 cells treated with either DMSO 
(DMSO Exos), or with 50nM paclitaxel (PTX Exos), and transfected with either mock or 
survivin-specific siRNA as noted. (B) Western blot analysis using survivin and flotillin 
antibodies was performed on lysates prepared from cells transfected with mock or survivin-
specific siRNA, and on the exosomes they shed. (C) Results of the cell death assays described 
in (A) with NIH-3T3 fibroblasts as the recipient cells; relative cell death was determined after 
48 hours. (D) Results of the cell death assays described in (A) with SKBR3 breast cancer 
cells as the recipient cells; relative cell death was determined after 5 days. The experiments 
were performed a minimum of 3 separate times. The data shown represents the mean ± SD.  
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Exosomes derived from paclitaxel-treated cells promote chemoresistance. 
 Next, we wanted to expand our study by determining whether exosomes from paclitaxel-
treated MDAMB-231 cells could promote the survival of paclitaxel-treated recipient cells, as 
would occur in a tumor microenvironment. First, the influence of paclitaxel on SKBR3 cells was 
determined. Compared to SKBR3 cells treated with only DMSO, SKBR3 cell viability treated 
with the drug showed over a 40% increase in cell death (Figure 3.5A, compare bars 1 and 2). The 
paclitaxel-treated SKBR3 cells incubated with exosomes derived from DMSO-treated MDAMB-
231 cells did not significantly reduce the cell death rate (bars 2 and 3). In contrast, when the 
paclitaxel-treated SKBR3 cells were incubated with exosomes derived from paclitaxel-treated 
MDAMB-231 cells, the relative amount of cell death decreased to levels comparable to that for 
SKBR3 cells treated with DMSO (compare bars 1 and 4). To demonstrate the role of survivin in 
mediating this chemoresistance effect, the same experiment was performed, except that 
exosomes from the paclitaxel-treated MDAMB-231 cells were first depleted of survivin 
expression by siRNA (Figure 3.5B). The results of this experiment showed that survivin was 
required for exosomes derived from paclitaxel-treated cells to provide a survival advantage to 
paclitaxel-treated recipient SKBR3 cells.  
 
Discussion 
 EVs have garnered a good deal of attention in the past few years for their ability to 
mediate a wide range of signaling events, most notably in the context of cancer progression. The 
class of EVs known as exosomes has been strongly tied to the propagation of the transformed 
phenotype. For example, it has been shown that colon cancer cells expressing an activated 
mutant form of KRAS shed exosomes containing the mutant KRAS, and that it can be 
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Figure 3.5. Exosomes derived from paclitaxel treated cells provide a survival advantage 
to cells treated with paclitaxel that is lost upon survivin knock down.  
(A) Serum-starved SKBR3 breast cancer cells were treated with either DMSO (PTX 
treatment -) or with paclitaxel (PTX treatment +) to show the effects of paclitaxel alone on 
recipient cells (bars 1 and 2). Cell death assays were performed on the SKBR3 cells ± PTX 
cultured in the presence of exosomes derived from paclitaxel-treated MDAMB-231s. (B) 
Serum-starved SKBR3 cells were treated with 50nM paclitaxel and cultured with exosomes 
derived from MDAMB-231 cells (Exo donor 231s) treated with either DMSO (PTX treatment 
-) or with paclitaxel (PTX treatment +) , and transfected with either mock or survivin-specific 
siRNA, as indicated. Relative cell death was determined after 5 days. The experiments were 
performed a minimum of 3 separate times. The data shown represents the mean ± SD. 
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transferred to recipient cells expressing the wild-type form of the gene leading to the 
enhancement of three-dimensional growth and invasiveness of the recipient cells (39).  
In this study, we expand on the role of extracellular vesicles in cancer progression by 
describing their role in mediating cell survival. Specifically, we set out to determine if the 
chemotherapy agent paclitaxel had an impact on the properties of exosomes shed by an 
aggressive breast cancer cell line (MDAMB-231). We discovered that the MDAMB-231 cells 
treated with paclitaxel not only generated more exosomes, but that these exosomes were enriched 
with the anti-apoptotic factor survivin. Importantly, this enrichment could not be attributed to an 
obvious increase in the expression levels of survivin within the cells, or any detection of survivin 
in the larger microvesicle population before or after paclitaxel treatment.   
 The presence of survivin in the exosomes derived from paclitaxel-treated cells caused 
significant changes in the functional capabilities of these exosomes. Namely, these exosomes 
were able to strongly promote the survival of recipient cells (both fibroblasts and other breast 
cancer cell lines) exposed to serum starvation or paclitaxel treatment. However, when the 
paclitaxel-treated cells were first depleted of survivin expression using a survivin-specific 
siRNA, the exosomes were no longer able to mediate this outcome.  
The enrichment of survivin within exosomes is dependent on the disruption of 
microtubule dynamics. Because survivin interacts with the microtubules during cell cycle 
progression, it is possible that when microtubule dynamics are interrupted due to the treatment of 
cells with paclitaxel or nocodazole, survivin is released from interacting with microtubules and is 
now available to be packaged as exosomal cargo.  
As we have shown here, survivin enrichment in exosomes can have a profound impact on 
their ability to promote survival, even overcoming the challenge of chemotherapy treatment.  
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This suggests that within a heterogeneous tumor microenvironment, there could be a sharing of 
survivin-containing exosomes between cancer cells to confer a survival advantage to the tumor 
as a whole by increasing anti-apoptotic signals. Overall, this study provides a potential 
mechanism for a shared paclitaxel resistance through the transfer of exosomes.  
 
Materials and Methods 
Cell culture and transfections 
MBAMB231 and SKBR3 cells were maintained in RPMI with 10% fetal bovine serum, while 
NIH-3T3 cells were grown in DMEM containing 10% calf serum. Control and Survivin siRNAs 
(Cell Signaling) were introduced into cells with Lipofectamine 2000 (Invitrogen). Paclitaxel 
treatment was at 50nm unless otherwise noted.  
 
Immunofluorescence 
Cells grown on glass coverslips were either transfected without or with the indicated expression 
constructs, or with siRNAs, and then cultured as indicated. The cells were fixed with 3.7% 
(vol/vol) formaldehyde, permeabilized with phosphate buffered saline (PBS) containing 0.1% 
Triton-X100, and blocked with 10% bovine serum albumin diluted in PBS. The cells were 
stained with an anti-survivin antibody (Novus Biologicals), followed by incubation with Oregon 
green 488-conjugated secondary antibodies (Molecular Probes). Digital images of the cells were 
collected using a Zeiss fluorescence microscope and IPLABS software. 
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Isolation of vesicles and the preparation of exosome and cell lysates  
For the experiments performed involving exosomes, the conditioned media from 4 x106 serum-
starved cells (which is approximately the equivalent of two 150mm dishes of cells at 70% 
confluency) was collected and then subjected to two consecutive centrifugations at 300×g to 
clarify the media of whole cells and cell debris. The partially clarified media was filtered using a 
Steriflip PVDF filter with a 0.22µm pore size (Millipore) to remove vesicles larger than 0.22µm 
in diameter and the flow-through was retained. For cell-based assays the exosomes were 
collected using a centricon with 100,000 kDa size cut-off (Millipore), rinsed three times with 
PBS, and resuspended in serum-free medium. To generate exosome lysates, the vesicles that 
passed through the 0.22µm filter were pelleted at 100,000xg for 2 hours and lysed using 200μl of 
lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM 
NaVO4, 1 mM β-glycerol phosphate, and 1 μg/mL each of aprotinin and leupeptin). Whole cell 
lysates (WCLs) were prepared by rinsing the 150mm dishes of cells with PBS, adding 1mL of 
lysis buffer, and scraping the cells off the plate. The resulting exosome and cell lysates were then 
centrifuged at 13,000 rpm for 10 minutes to remove the Triton X-100 insoluble fraction.  
 
Immunoblot Analysis 
The protein concentrations of the WCLs and MV lysates were determined using the Bio-Rad DC 
protein assay (Bio-Rad). The lysates were normalized by protein concentration, resolved by 
SDS-PAGE, and then the proteins were transferred to PVDF membranes. The membranes were 
incubated with various primary antibodies including beta-actin (Abcam), Survivin (Novus 
Biologicals), and flotillin-2 (Cell Signaling), diluted in in 20 mM Tris, 135 mM NaCl, and 0.02% 
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Tween 20 (TBST). The primary antibodies were detected with HRP-conjugated secondary 
antibodies (Cell Signaling) followed by exposure to ECL reagent (Pierce). 
 
Cell Death Assay 
Parental NIH-3T3 cells were plated in each well of a six-well dish and then cultured in medium 
containing 2% calf serum or serum-free medium supplemented with or without 5×107 exosomes 
derived from MDAMB-231 breast cancer cells. Twenty-four hours later the cells were treated 
with an additional dose of freshly prepared exosomes. A day later (48 hours from the start of the 
assay) the cells were stained with DAPI for viewing by fluorescent microscopy. Assays 
evaluating the survival of SKBR3 cells were performed over the course of 5 days. Cells 
undergoing apoptosis were identified by nuclear condensation or blebbing and the percentage of 
cell death was calculated by the ratio of apoptotic cells to total cells for each condition at least 
three times and the results from each experiment were averaged.    
 
Nanoparticle Tracking Analysis (NTA) 
For particle concentration determinations, nanoparticle tracking analysis (NTA) was performed 
with a NanoSight NS300 (Malvern). The samples were diluted in PBS made from ultra-pure 
water and passed through the beam path and detected by the microscope as points of diffracted 
light moving rapidly under Brownian motion. A digital video of the particles was analyzed to 
determine the size of the individual particles based on their movement. Per sample, 5 videos of 
60 seconds were captured at 22°C. 
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Transmission electron microscopy (TEM) 
Five μl of an exosome preparation resuspended in PBS made from ultra-pure water were added 
to a carbon-coated, 300-mesh copper grid and then stained with 1.75% uranyl acetate. Once dry, 
the samples were imaged using the FEI T12 Spirit 120 kV field emission TEM at Cornell’s 
Center for Materials Research (CCMR), supported by NSF MRSEC award number: NSF DMR-
1120296. 
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CHAPTER 4 
Conclusions 
 
 The field of extracellular vesicles (EVs) is still in its infancy, however there have already 
been some exciting discoveries demonstrating the significance of these vesicles in many disease 
states, most notably in cancer progression. However, due to the growing appreciation that normal 
cell types also make EVs (1-4), there is now a need in the field to better understand how EVs 
shed by normal and transformed cells differ. Thus, for my first research project, as described in 
Chapter 2 of this thesis, I set out to determine how EV cargo and function changed upon the 
induction of cellular transformation.   
I discovered that focal adhesion kinase (FAK) is specifically enriched in the larger class 
of EVs known as MVs, after MEFs were induced to express onco-Dbl, a hyperactive form of a 
guanine nucleotide exchange factor (GEF) that potently activates the small GTPases Cdc42 and 
Rho (5-7). The MVs enriched with FAK were able to promote a strong cell survival response, as 
well as induce a transformed phenotype in NIH-3T3 fibroblasts, as indicated by their ability to 
form colonies in soft agar. I then went on to show that the ability of the MVs derived from the 
transformed MEFs to mediate these outcomes was dependent on FAK, as depletion of FAK from 
the MVs using siRNAs, or inhibition of FAK activity associated with the MVs by treating them 
with a FAK-specific inhibitor, reversed these effects.  
An interesting point raised in this study is that the FAK expression levels in the MEFs did 
not change significantly after the induction of cellular transformation (i.e. by expression of onco-
Dbl). Thus, the large increase in the levels of FAK seen in the MVs derived from the 
transformed MEFs cannot simply be explained by changes in gene transcription. Rather, these 
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findings suggest that there is a difference in the way that cells direct specific cargo to MVs 
depending on whether they are normal (non-transformed) or transformed. To date, there are only 
a few studies that have focused on understanding the mechanisms underlying the sorting of cargo 
into EVs. For example, the small GTPase KRAS, and the nuclear ribonucleoprotein A2B1 
(hnRNPA2B1), have been implicated in the bulk sorting of miRNA into exosomes, while post-
translational modifications, such as sumoylation and GPI anchors, have been shown to influence 
sorting of EV cargo (8-10). However, whether these mechanisms are deregulated in transformed 
cells such that more FAK is recruited into MVs is currently unknown. Our inducible MEF 
system provides us a unique opportunity to investigate this question further. For example, further 
studies could include expressing truncated forms of FAK to determine if there is a specific 
domain in FAK required for its enrichment in MVs derived from transformed cells. Additionally, 
it would be valuable to identify proteins that differentially interact with FAK in control (non-
transformed) MEFs versus MEFs expressing onco-Dbl, as these proteins could potentially 
account for the differential expression of FAK in MVs derived from transformed MEFs, as well 
as cancer cell lines.  
In the pursuit of understanding the roles played by the smaller class of EVs that are 
generated by the fusion of MVBs with the plasma membrane, I also investigated whether 
exosome cargo and function could be potentially influenced by subjecting cancer cells to 
chemotherapies. Thus, I treated MDAMB-231 cells, a highly aggressive, triple negative breast 
cancer cell line, with the chemotherapy drug paclitaxel, and looked to see whether there were 
any changes in the exosomes generated by these cells. My initial expectation was that proteins 
destined to be included as exosome cargo would use microtubules as a trafficking mechanism, 
and that the disruption of the microtubule network using the microtubule stabilizer paclitaxel, 
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would prevent the enrichment of at least some cargo in exosomes. However, to my surprise, I 
found that there was as large increase in the amount of the anti-apoptotic protein survivin present 
in exosomes shed by paclitaxel-treated MDAMB-231 cells.  
The third chapter of this thesis describes the consequences of paclitaxel-treated 
MDAMB-231 cells shedding exosomes enriched with survivin. Survivin is a member of the 
inhibitor of apoptosis family of proteins and is normally only expressed during early 
embryogenesis. However, survivin expression is frequently upregulated in aggressive cancer 
cells (11-13). Because survivin expression and localization can be altered in response to a variety 
of cell stresses (14), I wanted to determine if the enrichment of survivin in exosomes was 
specific to paclitaxel. Interestingly, I found that there was no significant increase in the amounts 
of survivin detected in the exosomes generated by MDAMB-231 cells exposed to a variety of 
growth factor receptor inhibitors, cytoskeleton disruptors, kinase inhibitors, or inhibitors of DNA 
synthesis. The only inhibitor capable of enriching survivin in exosomes like paclitaxel was 
another modifier of microtubules, nocodazole. This is particularly intriguing because nocodazole 
functions by enhancing the catastrophic disassembly of microtubules, whereas paclitaxel 
stabilizes assembled microtubule subunits to prevent the proper progression through the cell 
cycle (15-18). This suggests that survivin enrichment in exosomes is not a general cell stress 
response, and is specific to the disruption of normal microtubule dynamics.   
The exact molecular mechanism by which the disassembly or stabilization of 
microtubules in cancer cells leads to the enrichment of survivin in exosomes is currently under 
investigation in the laboratory. Preliminary data generated by Arash Latifkar, a fellow graduate 
student in the group, suggests that the NAD-dependent deacetylase Sirtuin 1 (Sirt1) may be 
involved in this process. It has been previously reported that Sirt1 expression is down regulated 
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by paclitaxel, and combined with the finding that Sirt1 regulates survivin (19, 20), raises the 
interesting possibility that Sirt1 may mediate the ability of paclitaxel to increase the levels of 
survivin in exosomes. Consistent with this idea, Arash has also recently found that transfecting 
MDABM-231 cells with siRNAs targeting Sirt1 leads to exosomes that contain more survivin, 
similar to paclitaxel treatment.  
Through my studies, I have examined the biological significance of exosomes enriched 
with survivin. Specifically, I found that the exosomes derived from control MDAMB-231 cells 
were able to promote the survival of serum-starved NIH-3T3 fibroblasts by approximately 30%. 
However, those collected from MDAMB-231 cells treated with paclitaxel, promoted cell 
survival by almost 80%. I went on to show the ability of the exosomes from the cancer cells 
treated with the chemotherapy to promote survival was due to the increase in survivin levels, as 
depletion of survivin from these exosomes by siRNA completely eliminated this survival 
advantage.  
In the clinical setting, acquired resistance to paclitaxel is common (18, 21), so I also 
investigated whether exosomes from paclitaxel-treated MDAMB-231 cells could promote the 
survival of recipient cancer cells exposed to the same chemotherapy, as would occur in a tumor 
microenvironment. When paclitaxel-treated SKBR3 breast cancer cells were incubated with 
exosomes derived from paclitaxel-treated MDAMB-231 cells, chemoresistance occurred. Once 
again, the exosome-mediated survival advantage could be eliminated when survivin was depleted 
from the exosomes. This provides an example where chemotherapy treatment can alter exosomal 
cargo in order to transfer a survival signal within the tumor microenvironment, leading to drug 
resistance.  
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EVs are potent mediators of cellular function within a tumor microenvironment. Cancer 
cells are able to transmit signals of growth and survival to neighboring cancer cells and stromal 
cells to propagate the transformed phenotype (22-25). The enrichment of FAK and survivin in 
EVs derived from cancer cells appear to be two proteins in EVs that play important roles in 
promoting the effects of EVs. These findings are highlighted in Figure 4.1, which shows a cancer 
cell shedding both MVs and exosomes into the surrounding microenvironment. The EVs can 
then be taken up by neighboring cancer cells, as well as normal cells, to promote their growth 
and survival. These cancer-specific EVs also have the potential to get into the bloodstream where 
they can have an effect at a distant site, or be isolated from the serum of cancer patients for use 
as a source of diagnostic markers.  
The search for cancer-specific biomarkers has expanded greatly with the finding that EVs 
derived from tumors can be detected in the bloodstream of patients known as a “liquid biopsy” 
(26-28). This has the potential to provide valuable data for patient care, especially for 
heterogeneous tumors where a normal biopsy would likely only capture a small fraction of the 
tumor, and for tumors that may require invasive surgeries in order to acquire a biopsy, for 
example in the case of brain tumors (29). Any of the macromolecules contained within EVs can 
have the potential for being used as diagnostic markers of cancer, as well as for determining the 
genetic makeup of the tumor for proper selection of therapeutic agents, or gauging therapy 
response (30).  
The findings from the studies presented in Chapters 2 and 3 of this thesis are especially 
exciting when coupled with the observation that FAK and survivin are only found in EVs 
derived from oncogenically transformed cells. FAK is present in the MVs derived from highly 
aggressive breast cancer cell lines, but cannot be detected in the MVs derived from the non-
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Figure 4.1 
Diagram depicting EVs within the tumor microenvironment.  
Cancer cells shed microvesicles containing FAK that increase the growth and survival of 
neighboring cells. After treating the cancer cells with paclitaxel, exosomes enriched with 
survivin are released and can promote the growth of recipient cancer cells.  
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transformed mammary epithelial cell line MCF-10A. This opens the door to the possibility that 
the detection of FAK in MVs isolated from patients could be used as an indicator of cancer. 
Additionally, survivin is specifically enriched in exosomes derived from cancer cells treated with 
paclitaxel, suggesting that the detection of survivin in exosomes from patients treated with this 
chemotherapy could be used as a marker of drug resistance. 
Ultimately, it will be important to expand my findings to in vivo models. For example, 
MDAMB-231 cells could be injected into mice to allow tumor formation. Once a tumor has 
formed, the plasma from the mice could be collected and the MVs isolated. The MVs could then 
be evaluated for the expression of FAK. Additionally, the tumor-bearing mice could be treated 
with DMSO or paclitaxel to determine if survivin can be detected in exosomes derived from the 
plasma of mice treated with the chemotherapy.  
EVs have the potential to dramatically alter how we diagnose and treat diseases, 
especially cancer. However, there is still a significant amount of basic research needed in the 
field before we will truly understand the mechanisms behind EV formation, cargo sorting, and 
interactions with recipient cells. It has recently emerged that there may be sub-classes of EVs 
beyond the distinction between MVs and exosomes (31, 32), highlighting the need for stringent 
biochemical characterization of the different vesicle populations. With this thesis, I have 
contributed to our knowledge of the cargo and biological impact of different classes of 
extracellular vesicles shed by oncogenically transformed cells and how they play a role in 
promoting cell survival, growth, and chemotherapy resistance.  
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